WO2014031792A2 - Methods of treating epilepsy or tatus epilepticus - Google Patents

Methods of treating epilepsy or tatus epilepticus Download PDF

Info

Publication number
WO2014031792A2
WO2014031792A2 PCT/US2013/056062 US2013056062W WO2014031792A2 WO 2014031792 A2 WO2014031792 A2 WO 2014031792A2 US 2013056062 W US2013056062 W US 2013056062W WO 2014031792 A2 WO2014031792 A2 WO 2014031792A2
Authority
WO
WIPO (PCT)
Prior art keywords
dose
allopregnanolone
cyclodextrin
administration
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/056062
Other languages
English (en)
French (fr)
Other versions
WO2014031792A3 (en
Inventor
Kiran Reddy
Stephen Jay KANES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics Inc
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2015002252A priority Critical patent/MX2015002252A/es
Priority to SG11201501911RA priority patent/SG11201501911RA/en
Priority to RS20211597A priority patent/RS62761B1/sr
Priority to IL304912A priority patent/IL304912A/en
Priority to KR1020157007115A priority patent/KR102121633B1/ko
Priority to NZ705410A priority patent/NZ705410A/en
Priority to BR112015003747A priority patent/BR112015003747A2/pt
Priority to CA2882708A priority patent/CA2882708A1/en
Priority to HRP20220005TT priority patent/HRP20220005T1/hr
Priority to PL13830765T priority patent/PL2887944T3/pl
Priority to EP21200457.6A priority patent/EP3957309A1/en
Priority to EP13830765.7A priority patent/EP2887944B1/en
Priority to SM20220006T priority patent/SMT202200006T1/it
Priority to JP2015528638A priority patent/JP6355633B2/ja
Priority to ES13830765T priority patent/ES2902684T3/es
Priority to CN201380053788.6A priority patent/CN104736159A/zh
Priority to BR122021022560-5A priority patent/BR122021022560B1/pt
Priority to SI201331956T priority patent/SI2887944T1/sl
Priority to AU2013305767A priority patent/AU2013305767B2/en
Priority to LTEPPCT/US2013/056062T priority patent/LT2887944T/lt
Priority to KR1020207015890A priority patent/KR102305359B1/ko
Priority to RU2015109956A priority patent/RU2667010C2/ru
Priority to DK13830765.7T priority patent/DK2887944T3/da
Priority to IL294306A priority patent/IL294306B2/en
Priority to IL275725A priority patent/IL275725B/en
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Priority to HK15109426.8A priority patent/HK1209025B/en
Publication of WO2014031792A2 publication Critical patent/WO2014031792A2/en
Publication of WO2014031792A3 publication Critical patent/WO2014031792A3/en
Priority to ZA2015/01188A priority patent/ZA201501188B/en
Anticipated expiration legal-status Critical
Priority to IL237352A priority patent/IL237352B/en
Priority to PH12015500482A priority patent/PH12015500482A1/en
Priority to AU2018220028A priority patent/AU2018220028B2/en
Priority to IL264414A priority patent/IL264414B/en
Priority to PH12020500065A priority patent/PH12020500065A1/en
Priority to AU2020204359A priority patent/AU2020204359A1/en
Priority to CY20221100012T priority patent/CY1125070T1/el
Priority to AU2022202277A priority patent/AU2022202277A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention generally relates to methods of treating epilepsy or status epilepticus by administering a neuroactive steroid.
  • convulsive status epilepticus e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus
  • non-convulsive status epilepticus e.g., generalized status epilepticus, complex partial status epilepticus
  • the invention features a method of treating a subject having epilepsy or status epilepticus by administering in combination to the subject a neuroative steroid and a benzodiazepine.
  • the method further comprises administering at least one of the neuroative steroid or benzodiazepine parenterally (e.g., intranasally, buccally, intravenously or intramuscularly, for example,
  • both the neuroative steroid and benzodiazepine are administered parenterally.
  • the neuroative steroid and benzodiazepine are co-administered (e.g., administered simultaneously). In some embodiments, the neuroative steroid and benzodiazepine are administered sequentially. In some embodiments, neuroative steroid and benzodiazepine are administered in a single dosage form.
  • both of the agents should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a in the absence of the combination regimen.
  • the agents may be administered separately, as part of a multiple dose regimen.
  • the agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.
  • the neuroactive steroid is a progestin derivative, e.g.,
  • the neuroactive steroid is allopregnanolone.
  • the neruroactive steroid e.g., alloprenanolone
  • parenteral administration e.g., intranasally, buccally, intravenously or intramuscularly, for example, intravenously or intramuscularly.
  • the neneuroactive steroid e.g., allopregnanolone
  • a composition comprising a cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex, a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®.
  • the cyclodextrin is a ⁇ -cyclodextrin. In an embodiment, the cyclodextrin is a sulfo butyl ether ⁇ -cyclodextrin. In an embodiment, the cyclodextrin is
  • the cyclodextrin is a ⁇ -cyclodextrin disclosed in U.S. Patent Nos. 5,874,418; 6,046, 177; or 7,635,733, which are herein incorporated by reference.
  • the neuroactive steroid is a progestin derivative, e.g.,
  • allopregnanolone, and the cyclodextrin is a ⁇ -cyclodextrin.
  • the neuroactive steroid is allopregnanolone and the cyclodextrin is CAPTISOL®.
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • a ⁇ -cyclodextrin e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • a ⁇ -cyclodextrin e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising the neuroactive steroid at a concentration between 0.25-30mg/mL, 0.5-30mg/mL; l-30mg/mL; 5- 30mg/mL, 10-30mg/mL; 15-30mg/mL, 0.25-20mg/mL; 0.5-20mg/mL; l-20mg/mL, 0.5-20mg/mL; l-20mg/mL, 5-20mg/mL, 10-20mg/mL, 0.25-15mg/mL, 0.5- 15mg/mL; 0.5- 10m
  • the neuroactive steroid e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising the neuroactive steroid at a concentration of 0.25mg/mL, 0.5mg/mL; l .Omg/mL; 1.5mg/mL; 2.0mg/mL; 2.5mg/mL; 3.0mg/mL; 3.5mg/mL; 4.0mg/mL;
  • the neuroactive steroid e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising the neuroactive steroid at a concentration of 1.5mg/mL.
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising the neuroactive steroid at a concentration of 5mg/mL.
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising the neuroactive steroid at a concentration of 15mg/mL.
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • a ⁇ -cyclodextrin e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • complex is formulated as an aqueous composition comprising between 2.5-40%, 2.5-30%, 2.5-20%, 2.5- 10%, 5-40%, 5-30%, 5-20%, 5-10%, 6-40%, 6-30%, 6-20%, 6- 10%, 10-40%, 10-30%, 10-20%, 20-40%, 20-30%, 25- 40%, 25-30%, 3- 10%, 4.5-7.5%, 5-7%, 5.5-6.5% of the cyclodextrin, e.g., CAPTISOL®.
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • complex is formulated as an aqueous composition comprising 2.5%, 3%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, 10%, 15%, 20%, 25%, 30%, 35% or 40% of the cyclodextrin, e.g., CAPTISOL®.
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • a ⁇ - cyclodextrin e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®
  • a ⁇ -cyclodextrin e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • a ⁇ -cyclodextrin e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the allopregnanolone and CAPTISOL® complex is formulated as an aqueous composition with a pH between 3- 10, 4-9, 4-8, 4-7, 4-6, 4-5, 5-9, 5-8, 5-7, 5-6, 4.5-7.5, or 5.5-7.5.
  • the allopregnanolone and CAPTISOL® complex is formulated as an aqueous composition with a pH about 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, or 9.
  • the allopregnanolone and CAPTISOL® complex is formulated as an aqueous composition with a pH about 6.
  • a drug-degrading agent as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution comprising 300 mg of the cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, per mL of solution in a cell having a 1cm path length.
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • a color forming agent due to a color forming agent, as determined by UV/vis spectrophotometry at a wavelength of 320 nm to 350 nm for an aqueous solution comprising 500 mg of the cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, per mL of solution in a cell having a 1cm path length.
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, further comprises: less than 20 ppm of a sulfoalkylating agent; less than 0.5% wt. of an
  • underivatized cyclodextrin less than 1% wt. of an alkali metal halide salt; and less than 0.25% wt. of a hydrolyzed sulfoalkylating agent.
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • a drug-degrading agent as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution comprising 500 mg of the cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, per mL of solution in a cell having a 1 cm path length.
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, further comprises: less than 50 ppm of a phosphate; less than 10 ppm of a sulfoalkylating agent; less than 0.2% wt. of an underivatized cyclodextrin; less than 0.5% wt.
  • cyclodextrin e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, has an absorption of less than 0.2 A.U.
  • aqueous solution comprising 500 mg of the cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, per mL of solution in a cell having a 1 cm path length.
  • a ⁇ -cyclodextrin e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, further comprises: less than 10 ppm of a phosphate; less than 2 ppm of a sulfoalkylating agent; less than 0.1% wt. of an underivatized cyclodextrin; less than 0.2% wt.
  • cyclodextrin e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, has an absorption of less than 0.1 A.U.
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g.,
  • CAPTISOL® per mL of solution in a cell having a 1 cm path length.
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, further comprises: less than 5 ppm of a phosphate; less than 0.1% wt. of an alkali metal halide salt; and less than 0.05% wt. of a hydrolyzed sulfoalkylating agent.
  • the neuroactive steroid (e.g., allopregnanolone) and CAPTISOL® complex is formulated as an aqueous composition and is administered within 10 hours, 8 hours, 5 hours, 3 hours, 1 hour, or 0.5 hour after a seizure, e.g., a status epileptic seizure, e.g., a refractory status epileptic seizure has started.
  • a seizure e.g., a status epileptic seizure, e.g., a refractory status epileptic seizure has started.
  • the allopregnanolone and CAPTISOL® complex is formulated as an aqueous composition and is administered within 60 minutes, 45 minutes, 30 minutes, 15 minutes, 10 minutes, or 5 minutes after a seizure, e.g., a status epileptic seizure, e.g., a refractory status epileptic seizure has started.
  • a seizure e.g., a status epileptic seizure, e.g., a refractory status epileptic seizure has started.
  • the the neuroactive steroid (e.g., allopregnanolone) and CAPTISOL® complex is formulated as an aqueous composition and is administered after a seizure, e.g., a status epileptic seizure, e.g., a refractory status epileptic seizure has lasted 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes or 60 minutes.
  • a seizure e.g., a status epileptic seizure, e.g., a refractory status epileptic seizure has lasted 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes or 60 minutes.
  • the neuroactive steroid (e.g., allopregnanolone) and CAPTISOL® complex is formulated as an aqueous composition and is administered prior to the onset of a seizure, e.g., a status epileptic seizure, e.g., a refractory status epileptic seizure.
  • a seizure e.g., a status epileptic seizure, e.g., a refractory status epileptic seizure.
  • the benzodiazepine is clonazepam, lorazepam, midazolam, or diazepam.
  • the benzodiazepine is formulated for oral delivery. In some embodiments, the benzodiazepine is formulated for parenteral delivery (e.g., intranasally, buccally, intravenously or intramuscularly, for example, intravenously or intramuscularly).
  • parenteral delivery e.g., intranasally, buccally, intravenously or intramuscularly, for example, intravenously or intramuscularly.
  • both the neuroactive steroid and the benzodiazepine are formulated for parenteral delivery (e.g., intranasally, buccally, intravenously or intramuscularly, for example, intravenously or intramuscularly).
  • the neuroactive steroid such as allopregnanolone and benzodiazepine
  • the neuroactive steroid when administered in combination, are administered in an amount sufficient to achieve burst suppression (e.g., a predetermined burst suppression pattern, e.g., inter-burst intervals of between 2- 30 seconds; as measured by a method of neurophysiological monitoring, e.g., EEG, CFM).
  • burst suppression e.g., a predetermined burst suppression pattern, e.g., inter-burst intervals of between 2- 30 seconds; as measured by a method of neurophysiological monitoring, e.g., EEG, CFM.
  • the neuroactive steroid such as allopregnanolone and benzodiazepine
  • when administered in combination is administered at a dose sufficient to achieve a predetermined burst suppression pattern, e.g., inter-burst intervals of between 2-30 seconds, 5-30 seconds, 10-30 seconds, 15-30 seconds, 1-30 seconds, 0-30 seconds, 2-20 seconds, 2- 10 seconds, 5-20 seconds, 10-20 seconds, 15-25 seconds, 5-15 seconds or 5-10 seconds; as measured by a method of
  • neurophysiological monitoring e.g., EEG, CFM.
  • the invention features a method of treating a subject (e.g., human subject) having a seizure-related disorder, e.g., status epilepticus (SE), e.g., refractory status epilepticus (RSE) or super-refractory status epilepticus (SRSE), comprising: administering to said subject (e.g., human subject), an effective amount of allopregnanolone, wherein, concurrent with said
  • SE status epilepticus
  • RSE refractory status epilepticus
  • SRSE super-refractory status epilepticus
  • said subject e.g., human subject
  • said subject is under general anesthesia, thereby treating said subject (e.g., human subject).
  • the invention features a method of treating a subject (e.g., human subject) having a seizure-related disorder, e.g., status epilepticus (SE), e.g., refractory status epilepticus (RSE) or super-refractory status epilepticus (SRSE), comprising administering a first dose, e.g., a load dose, of allopregnanolone, e.g., to a patient under general anesthesia; administering a second dose, e.g., maintenance dose, of allopregnanolone, which is lower than said first dose; and administering a third dose, e.g., a downward taper dose, of allopregnanolone, said allopregnanolone doses being sufficient to treat said subject (e.g., human subject).
  • SE status epilepticus
  • RSE refractory status epilepticus
  • SRSE super-refractory status epilepticus
  • said subject e.g., human subject
  • said subject is not under general anesthesia for at least a portion of the second dose.
  • said subject is not under general anesthesia for at least a portion of the third dose.
  • said subject is under general anesthesia during the administration of the first dose and during administration of a portion of the second dose, e.g., for at least, or up to, 6, 12, 24, or 47 hours of the second dose.
  • the second dose is administered over a period of time that is at least 60, 65, 70, 80, 90, 100, 110, 120 times longer in duration than that of said first dose. In some embodiments, the second dose is administered over a period of time that not more than 80, 90, 100, 110, 120, 130, or 140 times longer in duration than that of said first dose.
  • the second dose is administered over a period of time that at least 2, 3, 4, 5, 6 times longer in duration than that of said third dose. In some embodiments, the second dose is administered over a period of time that not more than 5, 6, 7, 8, 9, or 10 times longer in duration than that of said third dose.
  • the infusion rate e.g., amount of allopregnanolone delivered/unit time in the second dose, e.g., as measured in ⁇ g/kg/hour, is at least 2, 3, 4, 5, or 6 times lower than that of the first dose.
  • one, two or all of said doses are injected, e.g., IV administrations.
  • said subject e.g., human subject
  • a first line treatment e.g., a benzodiazepine (e.g. midazolam), e.g., as evidenced by a failure to induce an EEG pattern of burst suppression, failure to control seizure, continued seizure activity on EEG recording after 24 hours or more on the first line treatment, or failure to wean from the first line treatment without resuming seizure activity as evidenced by EEG recording.
  • said subject e.g., human subject
  • said subject has failed to respond to a second line treatment, e.g., phenytoin, fos-phenytoin, valproate, phenobarbitol, or levetiracetam, e.g., as evidenced by a failure to induce an EEG pattern of burst suppression, failure to control seizure, continued seizure activity on EEG recording after 24 hours or more on the first line treatment, or failure to wean from the first line treatment without resuming seizure activity as evidenced by EEG recording.
  • the method further comprises administering an amount of an aesthetic effective to place said subject (e.g., human subject) under general anesthesia.
  • said anesthetic is selected from a benzodiazepine (e.g. midazolam), propofol, and pentobarbital.
  • the method further comprises a weaning period in which said subject (e.g., human subject) is weaned from said general anesthesia.
  • said weaning period is initiated during the administration of said second dose.
  • said weaning period is completed during the administration of said second dose.
  • said weaning period is initiated within 12, 24, 36, 48, 60 or 72 hours after initiation or completion of the first dose of allopregnanolone.
  • said weaning period is initiated at 48 hours after initiation or completion of the first dose of allopregnanolone.
  • said weaning period is 18 to 30 hours, 20 to 28 hours, or 22 to 26 hours in duration.
  • said weaning period is 24 hours in duration.
  • the administration of allopregnanolone is initiated within a preselected period of time, wherein said period begins with: the administration of said anesthetic; or the induction of general anesthesia.
  • said preselected period is not longer than 48, 24, 12, 6, 5, 4, 3, 2, or 1 hour. In some embodiments, said preselected period is not longer than 120, 60, 30, 15, or 5 minutes.
  • said second dose is initiated while the subject (e.g., human subject) is under general anesthesia.
  • the amount of allopregnanolone delivered per hour in said second dose is the same or lower than the amount delivered per hour in said first dose.
  • the administration of the first dose of allopregnanolone is initiated within a preselected period of time, wherein said period begins with: the administration of said anesthetic or the induction of general anesthesia.
  • said preselected period is at least 6, 12, 24, 48 or 60 hours. In some embodiments, said preselected period is not longer than 24, 48, or 60 hours. In some embodiments, said preselected period is between 2 to 120, 2 to 60, 4 to 120, 4 to 60, 4 to 48, 4 to 36, or 4 to 24 hours. In some embodiments, said preselected period is not longer than 48, 24, 12, 6, 5, 4, 3, 2, or 1 hour. In some embodiments, said preselected period is not longer than 120, 60, 30, 15, or 5 minutes.
  • said first dose is begun after failure of the subject (e.g., human subject) to respond to prior treatment.
  • the failure to respond is evidenced by one or more of, a failure to induce an EEG pattern of burst suppression, failure to control seizure, continued seizure activity on EEG recording after 24 hours or more on the first line treatment, or failure to wean from the first line treatment without resuming seizure activity as evidenced by EEG recording.
  • said prior treatment comprises administration of a first line treatment, e.g., a benzodiazepine (e.g. midazolam).
  • said prior treatment comprises administration of a second line treatment, e.g., phenytoin, fos-phenytoin, valproate, phenobarbitol, or levetiracetam.
  • said first dose is a load, e.g., bolus, dose. In some embodiments, said first dose results in a plasma concentration of 50 to 500 nM, 100 to 400 nM, or 200 to 300 nM. In some embodiments, said first dose results in a plasma concentration of 500 to 1000 nM, 600 to 900 nM, or 700 to 800 nM. In some embodiments, said first dose results in a plasma concentration of 1000 to 1500 nM, 1100 to 1400 nM, or 1200 to 1300 nM. In some embodiments, said first dose results in a plasma concentration of 1500 to 2000 nM, 1600 to 1900 nM, or 1700 to 1800 nM. In some embodiments, said first dose results in a plasma concentration of 2000 to 2500 nM, 2100 to 2400 nM, or 2200 to 2300 nM. In some embodiments, said first dose results in a plasma concentration of a plasma concentration of 2000 to 2500 nM, 2100 to 2400 nM, or
  • said first dose results in a plasma concentration of 300 to 800 nM, 400 to 700 nM, or 500 to 600 nM. In some embodiments, said first dose results in a plasma concentration of 800 to 1300 nM, 900 to 1200 nM, or 1000 to 1100 nM. In some embodiments, said first dose results in a plasma concentration of 1300 to 1800 nM, 1400 to 1700 nM, or 1500 to 1600 nM. In some embodiments, said first dose results in a plasma
  • said first dose results in a plasma concentration of 1800 to 2300 nM, 1900 to 2200 nM, or 2000 to 2100 nM.
  • said first dose results in a plasma concentration of 2300 to 2600 nM, 2400 to 2500 nM.
  • said first dose results in a plasma concentration of 300 to 400 nM, 400 to 500 nM, 600 to 700 nM, 800 to 900 nM, 1100 to 1200 nM, 1300 to 1400 nM, 1400 to 1500 nM, 1600 to 1700 nM, 1800 to 1900 nM, 1900 to 2000 nM, 2100 to 2200 nM, 2300 to 2400 nM.
  • said first dose results in a plasma concentration of 500 to 2500 nM, 500 to 1500 nM, 500 to 1000 nM, 500 to 800, or 500 to 600, nM. In some embodiments, said first dose results in a plasma concentration of 50 to 250 nM, 100 to 200 nM, or 140 to 160 nM. In some embodiments, said first dose results in a plasma concentration of 150 +/- 30 nM, 150 +/- 20 nM, 150 +/- 10 nM, or 150 nM.
  • the plasma concentration of said first dose is measured at a preselected time, e.g., at 10, 15, 20, 30, 45, 60 minutes, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours, 2, 3, 4 days after the initiation of said first dose.
  • said first dose is administered over a period of time that is not longer than 6, 5, 4, 3, 2, or 1 hour.
  • said first dose is administered over a period of time that is at least 10, 20, 30, 40, 50, 60, 70, 80, or 90 minutes in duration.
  • said first dose is administered over a period of time that is 30 to 120 minutes, 45 to 100 minutes, or 50 to 70 minutes, in duration.
  • said first dose is administered over a period of time that is 60 +/- 15 minutes, 60 +/- 10 minutes, 60 +/- 5 minutes, or 60 minutes, in duration.
  • said first dose is administered at a dosage rate of 200-3500 ⁇ g/kg/hour. In some embodiments, said first dose is administered at a dosage rate of 200-350 ⁇ g/kg/hour, 250-300 ⁇ g/kg/hour, 280-290 ⁇ g/kg/hour, 286 ⁇ g/kg/hour, 287 ⁇ g/kg/hour, or 288 ⁇ g/kg/hour, e.g., for one hour.
  • said second dose is a maintenance dose. In some embodiments, the administration said second dose is initiated within a preselected time period, wherein said time period begins with the administration of said anesthetic. In some embodiments, the administration said second dose is initiated within a preselected time period, wherein said time period begins with the induction of general anesthesia. In some embodiments, the administration said second dose is initiated within a preselected time period, wherein said time period begins with the beginning of the first dose. In some embodiments, the administration said second dose is initiated within a preselected time period, wherein said time period begins with the end of the first dose.
  • the administration said second dose is initiated within a preselected time period, wherein said time period begins with the achievement of a predetermined level of allopregnanolone, e.g., in the plasma. In some embodiments, said time period begins with the end of the first dose. In some embodiments, said preselected time period begins with beginning or ending of the
  • administration of the first dose and is not longer than 240, 180, 120, 60, 30, 15, or 5 minutes.
  • said preselected time period begins with beginning or ending of the
  • administration of the first dose is not longer than 90, 80, 70, or 60 minutes. In some embodiments,
  • the administration of the second dose begins no longer than 90, 80, 70, 60, or 30 minutes after the beginning or end of the administration of the first dose. In some embodiments, the administration of the second dose begins 50 to 70, 55 to 65, or 60 minutes after the beginning or end of the administration of the first dose. In some embodiments, the administration of the second dose begins no more than 60, 50, 40, 30, 20, 10, 5, 4, 3, 2, 1 minute after the end of administration of the first dose. In some embodiments, the administration of the second dose begins at the end of administration of the first dose.
  • the administration of the first dose and the initiation of second dose are performed with the same delivery device, e.g., with the same cannula or reservoir.
  • said second dose is administered for a period of time that is between 48 and 192 hours, 60 and 144 hours, 60 and 120 hours, 80 and 110 hours, and 90 and 100 hours. In some embodiments, said second dose is administered for 95+/-5 hours. In some embodiments, said second dose is administered for 95 hours.
  • said second dose results in a plasma concentration of 50 to 500 nM, 100 to 400 nM, or 200 to 300 nM. In some embodiments, said second dose results in a plasma concentration of 500 to 1000 nM, 600 to 900 nM, or 700 to 800 nM. In some embodiments, said second dose results in a plasma concentration of 1000 to 1500 nM, 1100 to 1400 nM, or 1200 to 1300 nM. In some embodiments, said second dose results in a plasma concentration of 1500 to 2000 nM, 1600 to 1900 nM, or 1700 to 1800 nM.
  • said second dose results in a plasma concentration of 2000 to 2500 nM, 2100 to 2400 nM, or 2200 to 2300 nM. In some embodiments, said second dose results in a plasma concentration of 300 to 800 nM, 400 to 700 nM, or 500 to 600 nM. In some embodiments, said second dose results in a plasma concentration of 800 to 1300 nM, 900 to 1200 nM, or 1000 to 1100 nM. In some embodiments, said first dose results in a plasma concentration of 1300 to 1800 nM, 1400 to 1700 nM, or 1500 to 1600 nM.
  • said second dose results in a plasma concentration of 1800 to 2300 nM, 1900 to 2200 nM, or 2000 to 2100 nM. In some embodiments, said second dose results in a plasma concentration of 2300 to 2600 nM, 2400 to 2500 nM. In some embodiments, said second dose results in a plasma concentration of 300 to 400 nM, 400 to 500 nM, 600 to 700 nM, 800 to 900 nM, 1100 to 1200 nM, 1300 to 1400 nM, 1400 to 1500 nM, 1600 to 1700 nM, 1800 to 1900 nM, 1900 to 2000 nM, 2100 to 2200 nM, 2300 to 2400 nM.
  • said second dose results in a plasma concentration of 500 to 2500 nM, 500 to 1500 nM, 500 to 1000 nM, 500 to 800 nM, or 500 to 600 nM. In some embodiments, said second dose results in a plasma concentration of 50 to 250 nM, 100 to 200 nM, or 140 to 160 nM.
  • said second dose results in a plasma concentration of 150 +/- 30 nM, 150 +/- 20 nM, 150 +/- 10 nM, or 150 nM
  • the plasma concentration of said second dose is measured at a preselected time, e.g., at 10, 15, 20, 30, 45, 60 minutes, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours, 2, 3, 4 days after the initiation of said second dose.
  • said second dose results in a plasma concentration of 150 nM, e.g., as measured at a preselected time, e.g., at 10, 15, 20, 30, 45, 60 minutes, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours, 2, 3, 4 days after the initiation of said second dose.
  • said second dose is administered at the same infusion rate, e.g.
  • the infusion rate e.g. amount of allopregnanolone delivered/unit time varies during the second dose.
  • said second dose is administered at an infusion rate, e.g. amount of
  • said second dose is administered at an infusion rate, e.g. amount of allopregnanolone/unit time of 25- 150 ⁇ g/kg/hour, 50-100 ⁇ g/kg/hour, 75-100 ⁇ g/kg/hour, 85 ⁇ g/kg/hour, 86 ⁇ g/kg/hour, or 87 ⁇ g/kg/hour.
  • said downward taper dose comprises administering a continuously decreasing amount allopregnanolone. In some embodiments, said downward taper dose comprises administering a continuously decreasing amount of allopregnanolone/unit time. In some
  • said downward taper dose comprises administering a plurality of step doses, wherein each subsequent step dose is lower than the step dose that precedes it. In some embodiments, said downward taper dose comprises administering a plurality of step doses, wherein each subsequent step dose delivers a lower amount of allopregnanolone/unit time than the step dose that precedes it.
  • the method comprises administering a first, second, and third step dose.
  • said first step dose is 60 to 90% of the second/maintenance dose; said second step dose is 40 to 70% of the second/maintenance dose; and said third step dose is 10 to 40% of the second/maintenance dose.
  • the amount of allopregnanolone is 60 to 90% of the second/maintenance dose; said second step dose is 40 to 70% of the second/maintenance dose; and said third step dose is 10 to 40% of the second/maintenance dose.
  • the amount of allopregnanolone is 60 to 90% of the second/maintenance dose
  • said second step dose is 40 to 70% of the second/maintenance dose
  • said third step dose is 10 to 40% of the second/maintenance dose.
  • the amount of allopregnanolone is 10 to 40% of the second/maintenance dose.
  • delivered/unit time in said first step dose is 60 to 90% of the amount of allopregnanolone
  • the amount of allopregnanolone delivered/unit time in said second/maintenance dose is 40 to 70% of the amount of allopregnanolone delivered/unit time in said second/maintenance dose; and the amount of allopregnanolone delivered/unit time in said third step dose is 10 to 40% of the infusion rate, e.g. amount of allopregnanolone delivered/unit time in said second/maintenance dose.
  • said first step dose is 70 to 80% of the second/maintenance dose; said second step dose is 40 to 60% of the second/maintenance dose; and said third step dose is 20 to 30% of the second/maintenance dose.
  • the amount of allopregnanolone delivered/unit time in said first step dose is 70 to 80% of the amount of allopregnanolone delivered/unit time in said second/maintenance dose; the amount of
  • allopregnanolone delivered/unit time in said second step dose is 40 to 60% of the amount of allopregnanolone delivered/unit time in said second/maintenance dose; and the amount of allopregnanolone delivered/unit time in said third step dose is 20 to 30% of the amount of allopregnanolone delivered/unit time in said second/maintenance dose.
  • said first step dose is 75% of the second/maintenance dose; said second step dose is 50% of the second/maintenance dose; and said third step dose is 25% of the second/maintenance dose.
  • the amount of allopregnanolone delivered/unit time in said first step dose is 75% of the amount of allopregnanolone delivered/unit time in said second/maintenance dose. In some embodiments, the amount of allopregnanolone delivered/unit time in said second step dose is 50% of the amount of allopregnanolone delivered/unit time in said second/maintenance dose. In some embodiments, the amount of allopregnanolone delivered/unit time in said third step dose is 25% of the amount of allopregnanolone delivered/unit time in said second/maintenance dose.
  • no allopregnanolone is administered to the subject (e.g., human subject) for at least 10, 20, 30, 40, 50, or 60 days, or until the patient has a subsequent episode of SRSE.
  • said first step dose is administered at an amount of
  • said first step dose is administered at an amount of allopregnanolone/unit time of 25- 1000 ⁇ g/kg/hour.
  • said first step dose is administered at an amount of allopregnanolone/unit time of 25- 100 ⁇ g/kg/hour, 50-75 ⁇ g/kg/hour, 60-70 ⁇ g/kg/hour, 63 ⁇ g/kg/hour, 64 ⁇ g/kg/hour, or 65 ⁇ g/kg/hour.
  • said second step dose is administered at an amount of allopregnanolone/unit time of 10-700
  • said second step dose is administered at an amount of allopregnanolone/unit time of 10-70 ⁇ g/kg/hour, 25-55 ⁇ g/kg/hour, 40-50 ⁇ g/kg/hour, 42
  • said third step dose is administered at an amount of allopregnanolone/unit time of 5-500 ⁇ g/kg/hour.
  • said third step dose is administered at an amount of allopregnanolone/unit time of 5- 50 ⁇ g/kg/hour, 10-35 ⁇ g/kg/hour, 15-25 ⁇ g/kg/hour, 20 ⁇ g/kg/hour, 21 ⁇ g/kg/hour, or 22 ⁇ g/kg/hour.
  • the third/taper dose begins no longer than 90, 80, 70, 60, or 30 minutes after the administration or end of the second dose. In some embodiments, the third/taper dose begins at the end of administration of the second dose.
  • the administration of the second dose and the initiation of third/taper dose are performed with the same delivery device, e.g., the same cannula.
  • the time between the end of the administration of said first step dose and the initiation of administration of said second step dose is less than 120, 60, 30, 15 or 5 minutes.
  • the time between the end of the administration of said second step dose and the initiation of administration of said third step dose is less than 120, 60, 30, 15 or 5 minutes.
  • said third dose is administered for a period of time that is between 10 and 100 hours, 12 and 96 hours, 12 and 48 hours, 16 and 32 hours, or 20 and 30 hours.
  • said third dose is administered over 24 hours.
  • the allopregnanolone is provided in a composition comprising a cyclodextrin, e.g., ⁇ -cyclodextrin, e.g., sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL.
  • the allopregnanolone is provided at a concentration of 0.1 to 10 mg/mL
  • the allopregnanolone is provided at a concentration of 0.1 , 0.5, 1, 1.25, 2.5, 3.75, 5, 6.25, 7.5, 8, 9, or 10 mg/mL allopregnanolone. In some embodiments, the allopregnanolone is provided at a concentration of 1.25 mg/mL allopregnanolone. In some embodiments, the allopregnanolone is provided at a concentration of 2.5 mg/mL allopregnanolone. In some embodiments, the allopregnanolone is provided at a concentration of 3.75 mg/mL allopregnanolone. In some embodiments, the allopregnanolone is provided at a concentration of 5 mg/mL allopregnanolone.
  • the cyclodextrin is present in the composition at 1-30%, 2-18%, 10- 15% by weight of cyclodextrin per volume of composition. In some embodiments, the cyclodextrin is present in the composition at 1, 2.5, 5, 10, 12, 13, 15, 30% by weight of cyclodextrin per volume of composition. In some embodiments, the cyclodextrin is present in the composition at 12% by weight of cyclodextrin per volume of composition.
  • the cyclodextrin is present in the composition at 1-30%, 2-18%, 10- 15% by weight of cyclodextrin per volume of composition and the allopregnanolone is provided at a concentration of 0.1, 0.5, 1, 1.25, 2.5, 3.75, 5, 6.25, 7.5, 8, 9, or 10 mg/mL allopregnanolone.
  • the cyclodextrin is present in the composition at 1, 2.5, 5, 10, 12, 13, 15, 30% by weight of cyclodextrin per volume of composition and the allopregnanolone is provided at a concentration of 0.1, 0.5, 1, 1.25, 2.5, 3.75, 5, 6.25, 7.5, 8, 9, or 10 mg/mL allopregnanolone.
  • the cyclodextrin is present in the composition at 12% by weight of cyclodextrin per volume of composition and the allopregnanolone is provided at a concentration of 5 mg/mL allopregnanolone. In some embodiments, the cyclodextrin is present in the composition at 12% by weight of cyclodextrin per volume of composition and the allopregnanolone is provided at a concentration of 3.75 mg/mL allopregnanolone. In some embodiments, the cyclodextrin is present in the composition at 12% by weight of cyclodextrin per volume of composition and the
  • allopregnanolone is provided at a concentration of 2.5 mg/mL allopregnanolone.
  • the cyclodextrin is present in the composition at 12% by weight of cyclodextrin per volume of composition and the allopregnanolone is provided at a concentration of 1.25 mg/mL allopregnanolone .
  • the method further comprises, evaluating the subject (e.g., human subject), wherein the evaluating comprises performing c-ECG. In some embodiments, the method comprises, evaluating the subject (e.g., human subject), wherein the evaluating comprises performing EEC In some embodiments, the method further comprises evaluating the subject (e.g., human subject) for serum chemistry (e.g., one or more of albumin, AST, ALT, bicarbonate, bilirubin, BUN, calcium, chloride, creatine kinase, lipase, creatinine, magnesium, potassium, sodium, total protein, or glucose).
  • serum chemistry e.g., one or more of albumin, AST, ALT, bicarbonate, bilirubin, BUN, calcium, chloride, creatine kinase, lipase, creatinine, magnesium, potassium, sodium, total protein, or glucose.
  • the method further comprises, evaluating the subject (e.g., human subject) for CBC (e.g., one or more of RBC, hemoglobin, hematocrit, MCV, MCH, MCHC, platelet count, WBC with differential including neutrophils, eosinophils, basophils, lymphocytes, or monocytes.
  • the method further comprises evaluating the subject (e.g., human subject) for serum allopregnanolone, progesterone, and 5cc-dihydrotestosterone.
  • the method comprises comparing an observed value with a reference value.
  • said subject e.g., human subject
  • said subject is evaluated for a parameter described herein during said weaning period.
  • the invention features a method of treating a subject (e.g., human subject) having, SE, RSE, or SRSE comprising: administering a first/load, e.g., bolus, dose concurrent with general anesthesia, wherein administration of said first dose: begins 2- 120 hours after induction of general anesthesia; lasts for 30-90 minutes; and results in a plasma level of allopregnanolone of 100- 2000 nM allopregnanolone; administering a second/maintenance dose, wherein, the administration of said second dose begins not longer than 1-60 minutes after the end of the second dose; lasts for 1- 6 days; and results in a plasma level of allopregnanolone of 100-2000 nM allopregnanolone;
  • a first/load e.g., bolus
  • administration of said first dose begins 2- 120 hours after induction of general anesthesia; lasts for 30-90 minutes; and results in a plasma level of allopregnanolone of 100- 2000
  • a third downward taper dose wherein, the administration of said third downward taper dose begins not longer than 1-60 minutes after the end of the third dose; lasts for 10- 100 hours; and results in a plasma level of allopregnanolone of 0- 1500 nM allopregnanolone; wherein, collectively, the administrations are provided in sufficient amount to treat said subject (e.g., human subject).
  • the method comprises administering a first/load, e.g., bolus, dose concurrent with general anesthesia, wherein administration of said first dose: begins 2-120 hours after induction of general anesthesia; lasts for 60 +/- 15 minutes; administering a first/load, e.g., bolus, dose concurrent with general anesthesia, wherein administration of said first dose: begins 2-120 hours after induction of general anesthesia; lasts for 60 +/- 15 minutes; administering a first/load, e.g., bolus, dose concurrent with general anesthesia, wherein administration of said first dose: begins 2-120 hours after induction of general anesthesia; lasts for 60 +/- 15 minutes; administering a first/load, e.g., bolus, dose concurrent with general anesthesia, wherein administration of said first dose: begins 2-120 hours after induction of general anesthesia; lasts for 60 +/- 15 minutes; administering a first/load, e.g., bolus, dose concurrent with general anesthesia, wherein administration of said first
  • second/maintenance dose wherein, the administration of said second dose begins not longer than 30 minutes after the end of the second dose; lasts for 70 to 110 hours; administering a third downward taper dose, wherein, the administration of said third downward taper dose begins not longer than 1- 60 minutes after the end of the third dose; lasts for 10-30 hours.
  • administering a first/load, e.g., bolus, dose concurrent with general anesthesia wherein administration of said first dose: begins 2-120 hours after induction of general anesthesia; lasts for 60 +/- 15 minutes; administering a second/maintenance dose, wherein, the administration of said second dose begins not longer than 30 minutes after the end of the second dose; lasts for 70 to 110 hours; and administering a third downward taper dose, wherein, the administration of said third downward taper dose begins not longer than 1-60 minutes after the end of the third dose; lasts for 24 +/- 2 hours and said third downward taper dose comprises a first, second, and third step dose.
  • a first/load e.g., bolus
  • administering a first/load, e.g., bolus, dose concurrent with general anesthesia wherein administration of said first dose lasts for 60 +/-15 minutes; administering a second/maintenance dose, wherein, the administration of said second dose begins not longer than 30 minutes after the end of the second dose; lasts for 85 to 105 hours; administering a third downward taper dose, wherein, the administration of said third downward taper dose begins not longer than 1- 60 minutes after the end of the third dose; lasts for 10-30 hours and: the amount of allopregnanolone delivered/unit time in said first step dose is 70 to 80% of the amount of allopregnanolone
  • the amount of allopregnanolone delivered/unit time in said second step dose is 40 to 60% of the amount of allopregnanolone delivered/unit time in said second/maintenance dose; and the amount of allopregnanolone delivered/unit time in said third step dose is 20 to 30% of the amount of allopregnanolone delivered/unit time in said
  • administering a first/load, e.g., bolus, dose concurrent with general anesthesia wherein administration of said first dose lasts for 60 +/-5 minutes; administering a second/maintenance dose, wherein, the administration of said second dose begins not longer than 30 minutes after the end of the second dose; lasts for 96+/-4 hours; administering a third downward taper dose, wherein, the administration of said third downward taper dose begins not longer than 1- 60 minutes after the end of the third dose; lasts for 24+/-2 hours and: the amount of
  • allopregnanolone delivered/unit time in said first step dose is 75% of the amount of
  • allopregnanolone delivered/unit time in said second step dose is 50% of the amount of
  • the method further comprises administering an amount of a composition selected from benzodiazepines (e.g., midazolam), propofol, barbiturates, and ketamine sufficient to place said subject (e.g., human subject) under general anesthesia;
  • a composition selected from benzodiazepines (e.g., midazolam), propofol, barbiturates, and ketamine sufficient to place said subject (e.g., human subject) under general anesthesia;
  • the invention features a kit comprising one or more of: a preparation of allopregnanolone, e.g., a plurality of preparations of allopregnanolone at a concentrations suitable for use at the first, second, and third doses; and instructions for use for treating a subject (e.g., human subject) having a seizure-related disorder, e.g., status epilepticus (SE), e.g., super-refractory status epilepticus (SRSE).
  • SE status epilepticus
  • SRSE super-refractory status epilepticus
  • the kit further comprises a suitable diluent (e.g., water, saline, cyclodextrin, e.g., ⁇ -cyclodextrin, e.g., sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL).
  • a suitable diluent e.g., water, saline, cyclodextrin, e.g., ⁇ -cyclodextrin, e.g., sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL.
  • the allopregnanolone is provided at a concentration of 0.1- 10 mg/mL allopregnanolone. In some embodiments, the allopregnanolone is provided at a concentration of 0.5- 7.5 mg/mL allopregnanolone. In some embodiments, the allopregnanolone is provided at a concentration of 1-6 mg/mL allopregnanolone. In some embodiments, the allopregnanolone is provided at a concentration of 5 mg/mL allopregnanolone. In some embodiments, the
  • allopregnanolone is provided at a concentration of 3.75 mg/mL allopregnanolone. In some embodiments, the allopregnanolone is provided at a concentration of 2.5 allopregnanolone. In some embodiments, the allopregnanolone is provided at a concentration of 1.25 mg/mL allopregnanolone.
  • the invention features a method of making a series of dosages, the method comprising combining a diluent and allopregnanolone in proportions to from dosage forms suitable for use as the first, second and one or more step doses for said third dose.
  • the invention features a method of adjusting the amount of diluents and or allopregnanolone flowing into or out of a delivery device, e.g., a catheter, reservoir, the method comprising altering, e.g., decreasing, the flow rate of allopregnanolone flowing into the delivery device, so as to release in succession, two or more of a first dosage, a second dosage and one or more step doses of the third dose.
  • a delivery device e.g., a catheter, reservoir
  • the invention features a method of treating a subject having seizure, epilepsy or status epilepticus by administering in combination to the subject a neuroactive steroid and a benzodiazepine or anesthetic/sedative.
  • the method further comprises administering at least one of the neuroactive steroid and benzodiazepine or anesthetic/sedative parenterally (e.g., intranasally, buccally, intravenously or intramuscularly, for example,
  • both the neuroactive steroid and benzodiazepine or anesthetic/sedative are administered parenterally.
  • the neuroactive steroid and benzodiazepine or anesthetic/sedative coadministered e.g., administered simultaneously, administered concurrently.
  • the neuroactive steroid and benzodiazepine or anesthetic/sedative are administered sequentially.
  • neuroactive steroid and benzodiazepine or anesthetic/sedative are administered in a single dosage form.
  • both of the agents should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in the absence of the combination regimen.
  • the agents may be administered separately, as part of a multiple dose regimen.
  • the agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.
  • the neuroactive steroid is a progestin derivative, e.g.,
  • the neuroactive steroid is allopregnanolone.
  • the neuroactive steroid e.g., allopregnanolone
  • parenteral administration e.g., intranasally, buccally, intravenously or intramuscularly, for example, intravenously or intramuscularly.
  • the neuroactive steroid e.g., allopregnanolone
  • a composition comprising a cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®, complex.
  • the cyclodextrin is a ⁇ -cyclodextrin. In an embodiment, the cyclodextrin is a sulfo butyl ether ⁇ -cyclodextrin. In an embodiment, the cyclodextrin is
  • the cyclodextrin is a ⁇ -cyclodextrin disclosed in U.S. Patent Nos. 5,874,418; 6,046, 177; or 7,635,733, which are herein incorporated by reference.
  • the neuroactive steroid is a progestin derivative, e.g.,
  • the neuroactive steroid is a progestin derivative, e.g., allopregnanolone, and the cyclodextrin is a sulfo butyl ether ⁇ - cyclodextrin.
  • the neuroactive steroid is allopregnanolone and the cyclodextrin is CAPTISOL®.
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • a ⁇ -cyclodextrin e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • a ⁇ -cyclodextrin e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising the neuroactive steroid at a concentration between 0.25-30mg/mL, 0.5-30mg/mL; l-30mg/mL; 5- 30mg/mL, 10-30mg/mL; 15-30mg/mL, 0.25-20mg/mL; 0.5-20mg/mL; l-20mg/mL, 0.5-20mg/mL; l-20mg/mL, 5-20mg/mL, 10-20mg/mL, 0.25-15mg/mL, 0.5- 15mg/mL; 0.5- 10m
  • the neuroactive steroid e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising the neuroactive steroid at a concentration of 0.25mg/mL, 0.5mg/mL; l .Omg/mL; 1.5mg/mL; 2.0mg/mL; 2.5mg/mL; 3.0mg/mL; 3.5mg/mL; 4.0mg/mL; 4.5mg/mL; 5.0mg/mL, 5.5mg/mL, 6.0mg/mL, 6.5mg/mL, 7.0mg/mL, 7.5mg/mL, 8.0mg/mL,
  • the neuroactive steroid e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising the neuroactive steroid at a concentration of 1.5mg/mL.
  • the neuroactive steroid e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • allopregnanolone, and cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising the neuroactive steroid at a concentration of 2.5mg/mL.
  • the neuroactive steroid e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • allopregnanolone, and cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising the neuroactive steroid at a concentration of 3.5mg/mL.
  • the neuroactive steroid e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • allopregnanolone, and cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising the neuroactive steroid at a concentration of 5 mg/mL.
  • the neuroactive steroid e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • allopregnanolone, and cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising the neuroactive steroid at a concentration of 6 mg/mL.
  • the neuroactive steroid e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • allopregnanolone, and cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising the neuroactive steroid at a concentration of 15 mg/mL.
  • the neuroactive steroid e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising the neuroactive steroid at a concentration of between 0.1-50 ⁇ ; 0.1-40 ⁇ ; 0.1-30 ⁇ ; 0.1-20 ⁇ ; 0.1-15 ⁇ ; 0.5-50 ⁇ ; 0.5-40 ⁇ ; 0.5-30 ⁇ ; 0.5-20 ⁇ ; 0.5- 15 ⁇ ; 1-50 ⁇ ; 1-40 ⁇ ; 1-30 ⁇ ; 1-20 ⁇ ; 1-15 ⁇ ; 2-50 ⁇ ; 2-40 ⁇ ; 2-30 ⁇ ; 2-20 ⁇ ; 2- 15 ⁇ ; 0.5- 15 ⁇ ; 1-15 ⁇ ; 2- 15 ⁇ ; 3- 15 ⁇ ; 1-20
  • the neuroactive steroid e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising the neuroactive steroid at a concentration of 0.1 ⁇ ; 0.5- 1 ⁇ ; 2 ⁇ ; 4 ⁇ ; 5 ⁇ ; 7 ⁇ ; 10 ⁇ ; 15 ⁇ ; 20 ⁇ ; 25 ⁇ ; 40 ⁇ ; 50 ⁇ .
  • the neuroactive steroid e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising the neuroactive steroid at a concentration of 1 ⁇ .
  • the neuroactive steroid e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising the neuroactive steroid at a concentration of 2 ⁇ .
  • the neuroactive steroid e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • allopregnanolone, and cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising the neuroactive steroid at a concentration of 5 ⁇ .
  • the neuroactive steroid e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • a ⁇ -cyclodextrin e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising between 2.5-40%, 2.5-30%, 2.5-20%, 2.5- 15%, 2.5-10%, 5- 40%, 5-30%, 5-20%, 5-15%, 5- 10%, 6-40%, 6-30%, 6-20%, 6- 10%, 6-20%, 6-30%, 10-40%, 10- 30%, 10-20%, 20-40%, 20-30%, 25-40%, 25-30%, 3- 10%, 3- 15%, 4.5-7.5%, 4- 13%, 5-7%, 5-13%, 5.5-6.5%, 7-13% by weight of the cyclodextrin, e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising 2.5%, 3%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, 10%, 12%, 15%, 20%, 25%, 30%, 35% or 40% by weight of the cyclodextrin, e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g., CAPTISOL
  • allopregnanolone, and cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • complex is formulated as an aqueous composition comprising 6% by weight of the cyclodextrin, e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®
  • a ⁇ -cyclodextrin e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®
  • CAPTISOL® sulfo butyl ether
  • complex formulated as an aqueous composition comprising 12% by weight of the cyclodextrin, e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • a ⁇ -cyclodextrin e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • a aqueous composition comprising 15% by weight of the cyclodextrin, e.g
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • a ⁇ -cyclodextrin e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • aqueous composition comprising 30% by weight of the cyclodextrin, e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®, at a concentration of 6% by weight of the cyclodextrin, e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g.,
  • allopregnanolone, and cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • complex is formulated as an aqueous composition comprising the neuroactive steroid, e.g., allopregnanolone, at a concentration of lOmg/mL, and the cyclodextrin, e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, at a concentration of 6% by weight of the cyclodextrin, e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • concentration of 6% by weight of the cyclodextrin e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®, at a concentration of 12% by weight of the cyclodextrin, e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g.,
  • allopregnanolone, and cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • complex is formulated as an aqueous composition comprising the neuroactive steroid, e.g., allopregnanolone, at a concentration of 1.5mg/mL, and the cyclodextrin, e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, at a concentration of 12% by weight of the cyclodextrin, e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • concentration of 12% by weight of the cyclodextrin e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • concentration of 12% by weight of the cyclodextrin e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • concentration of 12% by weight of the cyclodextrin e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • concentration of 12% by weight of the cyclodextrin e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • concentration of 12% by weight of the cyclodextrin e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®, at a concentration of 15% by weight of the cyclodextrin, e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g.,
  • allopregnanolone, and cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • complex is formulated as an aqueous composition comprising the neuroactive steroid, e.g., allopregnanolone, at a concentration of lOmg/mL, and the cyclodextrin, e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, at a concentration of 15% by weight of the cyclodextrin, e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • concentration of 15% by weight of the cyclodextrin e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex is formulated as an aqueous composition comprising the neuroactive steroid, e.g., allopregnanolone, at a concentration of 1.5mg/mL, and the cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®, at a concentration of 30% by weight of the cyclodextrin, e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g., all
  • allopregnanolone, and cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • complex is formulated as an aqueous composition comprising the neuroactive steroid, e.g., allopregnanolone, at a concentration of lOmg/mL, and the cyclodextrin, e.g., a ⁇ - cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, at a concentration of 30% by weight of the cyclodextrin, e.g., CAPTISOL® per weight of solution.
  • the neuroactive steroid e.g., allopregnanolone
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the neuroactive steroid e.g., allopregnanolone
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • concentration of 30% by weight of the cyclodextrin e.g., CAPTISOL® per weight of solution.
  • the allopregnanolone and CAPTISOL® complex is formulated as an aqueous composition with a pH between 3- 10, 4-9, 4-8, 4-7, 4-6, 4-5, 5-9, 5-8, 5-7, 5-6, 4.5-7.5, or 5.5-7.5.
  • the allopregnanolone and CAPTISOL® complex is formulated as an aqueous composition with a pH about 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, or 9.
  • the allopregnanolone and CAPTISOL® complex is formulated as an aqueous composition with a pH about 6.
  • the allopregnanolone and CAPTISOL® complex is formulated as an aqueous composition and is administered intravenously. In some embodiments, the allopregnanolone and CAPTISOL® complex is formulated as an aqueous composition and is administered
  • the allopregnanolone and CAPTISOL® complex is formulated as an aqueous composition and is administered for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive days. In some embodiments, the allopregnanolone and CAPTISOL® complex is formulated as an aqueous composition and is administered between 1-10, 1-5, 5- 10, 1-6, 2-6, 3-6, 4-5, or 1-9 consecutive days. In an embodiment, the allopregnanolone and CAPTISOL® complex is formulated as an aqueous composition and is administered for 5 consecutive days. In some embodiments, the duration of administration is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days. In some embodiments, the duration of administration is 3-7, 4-6, 4-5, or 5-6 days. In some embodiments, the duration of administration is 5 days.
  • the allopregnanolone and CAPTISOL® complex is formulated as an aqueous composition and is administered at the same dose for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive days.
  • the allopregnanolone and CAPTISOL® complex is formulated as an aqueous composition and is administered at a load, e.g., bolus, dose for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive days and then administered at a maintenance, e.g., infusion, dose for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive days.
  • a load e.g., bolus
  • a maintenance e.g., infusion
  • CAPTISOL® complex is formulated as an aqueous composition and is administered at a load, e.g., bolus, dose of 0.25mg/mL, 0.5mg/mL; l .Omg/mL; 1.5mg/mL; 2.0mg/mL; 2.5mg/mL; 3.0mg/mL; 3.5mg/mL; 4.0mg/mL; 4.5mg/mL; 5.0mg/mL, 5.5mg/mL, 6.0mg/mL, 6.5mg/mL, 7.0mg/mL, 7.5mg/mL, 8.0mg/mL, 8.5mg/mL, 9.0mg/mL, 9.5mg/mL, lOmg/mL, 15mg/mL, 20mg/mL,
  • a load e.g., bolus
  • neuroactive steroid e.g., allopregnanolone
  • a maintenance e.g., infusion, dose for 1, 2, 3, 4, 5, or 6 consecutive days of 0.25mg/mL
  • a maintenance e.g., infusion, dose described herein, is lower than a load, e.g., bolus, dose described herein.
  • a load e.g., bolus
  • a maintenance, e.g., infusion, dose described herein is the same as a load, e.g., bolus, dose described herein.
  • the maintenance, e.g., infusion, dose is less than 0.25mg/mL, 0.5mg/mL; l .Omg/mL; 1.5mg/mL; 2.0mg/mL; 2.5mg/mL; 3.0mg/mL; 3.5mg/mL;
  • 4.0mg/mL 4.5mg/mL; 5.0mg/mL, 5.5mg/mL, 6.0mg/mL, 6.5mg/mL, 7.0mg/mL, 7.5mg/mL, 8.0mg/mL, 8.5mg/mL, 9.0mg/mL, 9.5mg/mL, lOmg/mL, 15mg/mL, 20mg/mL, 25mg/mL, or 30 mg/mL.
  • the allopregnanolone and CAPTISOL® complex is formulated as an aqueous composition and is administered at a load, e.g., bolus, dose for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive days and then administered at a maintenance, e.g., infusion, dose for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive days and then administered at a taper dose for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive days.
  • a load e.g., bolus
  • a maintenance e.g., infusion
  • the allopregnanolone and CAPTISOL® complex is formulated as an aqueous composition and is administered at a load, e.g., bolus, dose for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive days and then administered at a maintenance, e.g., infusion, dose for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive days and then administered at a first step dose for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 hours.
  • a load e.g., bolus
  • a maintenance e.g., infusion
  • the allopregnanolone and CAPTISOL® complex is formulated as an aqueous composition and is administered at a load, e.g., bolus, dose for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive days and then administered at a maintenance, e.g., infusion, dose for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive days and then administered at a first step dose for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 hours and then administered at a second step dose for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 hours.
  • a load e.g., bolus
  • a maintenance e.g., infusion
  • the allopregnanolone and CAPTISOL® complex is formulated as an aqueous composition and is administered at a load, e.g., bolus, dose for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive days and then administered at a maintenance, e.g., infusion, dose for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive days and then administered at a first step dose for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 hours and then administered at a second step dose for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 hours and then administered at a third step dose for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 hours.
  • a load e.g., bolus
  • a maintenance e.g., infusion
  • the first, second, or third step dose is less than the maintenance, e.g., infusion, dose.
  • the second taper or third step dose is less than the first step dose.
  • the third step dose is less than the second step dose.
  • the first step dose is 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5% of the maintenance, e.g., infusion, dose.
  • the first step dose is between 95-50%, 75-50%, 85-50%, 90-50%, 80-50%, or 75- 100% of the maintenance, e.g., infusion, dose.
  • the first step dose is 75% of the maintenance, e.g., infusion, dose.
  • the second step dose is 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5% of the maintenance, e.g., infusion, dose.
  • the second step dose is between 95-30%, 75-30%, 85-30%, 60-30%, 70-30%, 50-30%, or 50-40% of the maintenance, e.g., infusion, dose.
  • the second step dose is 50% of the maintenance, e.g., infusion, dose.
  • the third step dose is 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5% of the maintenance, e.g., infusion, dose.
  • the third step dose is between 50-5%, 40-5%, 30-5%, 25-5%, 25-10%, 25-20%, or 25-40% of the maintenance, e.g., infusion, dose.
  • the second step dose is 50% of the maintenance, e.g., infusion, dose.
  • the third step dose is 25% of the maintenance, e.g., infusion, dose.
  • a composition comprising a neuroactive steroid, e.g., allopregnanolone, and cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, complex, comprises less than lOOppm of a phosphate, and the cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, has an absorption of less than 0.2 A.U.
  • a drug-degrading agent due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution comprising 300 mg of the cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, per mL of solution in a cell having a 1cm path length.
  • a cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®, has an absorption of less than 0.2 A.U.
  • a color forming agent due to a color forming agent, as determined by UV/vis spectrophotometry at a wavelength of 320 nm to 350 nm for an aqueous solution comprising 500 mg of the cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, per mL of solution in a cell having a 1cm path length.
  • a ⁇ -cyclodextrin e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®, further comprises: less than 20 ppm of a sulfoalkylating agent; less than 0.5% wt. of an underivatized cyclodextrin; less than 1% wt. of an alkali metal halide salt; and less than 0.25% wt. of a hydrolyzed sulfoalkylating agent.
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®, has an absorption of less than 0.2 A.U.
  • a drug-degrading agent due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution comprising 500 mg of the cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®, per mL of solution in a cell having a 1 cm path length.
  • a ⁇ -cyclodextrin e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®, further comprises: less than 50 ppm of a phosphate; less than 10 ppm of a sulfoalkylating agent; less than 0.2% wt. of an underivatized cyclodextrin; less than 0.5% wt. of an alkali metal halide salt; and less than 0.1 % wt.
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • CAPTISOL® a hydrolyzed sulfoalkylating agent
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • aqueous solution comprising 500 mg of the cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®, per mL of solution in a cell having a 1 cm path length.
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®, further comprises: less than 10 ppm of a phosphate; less than 2 ppm of a sulfoalkylating agent; less than 0.1% wt. of an underivatized cyclodextrin; less than 0.2% wt. of an alkali metal halide salt; and less than 0.08% wt.
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • CAPTISOL® a hydrolyzed sulfoalkylating agent
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®
  • aqueous solution comprising 500 mg of the cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®, per mL of solution in a cell having a 1 cm path length.
  • cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®
  • the cyclodextrin e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ - cyclodextrin, e.g., CAPTISOL®, further comprises: less than 5 ppm of a phosphate; less than 0.1% wt. of an alkali metal halide salt; and less than 0.05% wt. of a hydrolyzed sulfoalkylating agent.
  • the neuroactive steroid (e.g., allopregnanolone) and CAPTISOL® complex is formulated as an aqueous composition and is administered within 48 hours, 24 hours, 10 hours, 8 hours, 5 hours, 3 hours, 1 hour, or 0.5 hour after a seizure, e.g., a status epileptic seizure, e.g., a refractory status epileptic seizure has started.
  • the allopregnanolone and CAPTISOL® complex is formulated as an aqueous composition and is administered within 60 minutes, 45 minutes, 30 minutes, 15 minutes, 10 minutes, or 5 minutes after a seizure, e.g., a status epileptic seizure, e.g., a refractory status epileptic seizure has started.
  • a seizure e.g., a status epileptic seizure, e.g., a refractory status epileptic seizure has started.
  • the neuroactive steroid (e.g., allopregnanolone) and CAPTISOL® complex is formulated as an aqueous composition and is administered after a seizure, e.g., a status epileptic seizure, e.g., a refractory status epileptic seizure has lasted 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes or 60 minutes.
  • the neuroactive steroid (e.g., allopregnanolone) and CAPTISOL® complex is formulated as an aqueous composition and is administered prior to the onset of a seizure, e.g., a status epileptic seizure, e.g., a refractory status epileptic seizure.
  • the benzodiazepine is clonazepam, lorazepam, midazolam, or diazepam. In some embodiments, the benzodiazepine is formulated for oral delivery. In some embodiments, the benzodiazepine is formulated for parenteral delivery (e.g., intranasally, buccally, intravenously or intramuscularly, for example, intravenously or intramuscularly).
  • the anesthetic/sedative is propofol or a barbiturate, e.g., pentobarbital.
  • anesthetic/sedative are formulated for parenteral delivery (e.g., intranasally, buccally, intravenously or intramuscularly, for example, intravenously or intramuscularly).
  • the neuroactive steroid such as allopregnanolone and benzodiazepine or anesthetic/sedative, when administered in combination, are administered in an amount sufficient to achieve burst suppression (e.g., a predetermined burst suppression pattern, e.g., inter-burst intervals of between 2-30 seconds; as measured by a method of neurophysiological monitoring, e.g., EEG, CFM).
  • burst suppression e.g., a predetermined burst suppression pattern, e.g., inter-burst intervals of between 2-30 seconds; as measured by a method of neurophysiological monitoring, e.g., EEG, CFM.
  • the neuroactive steroid such as allopregnanolone and benzodiazepine or anesthetic/sedative, when administered in combination, is administered at a dose sufficient to achieve a predetermined burst suppression pattern, e.g., inter-burst intervals of between 2-30 seconds, 5-30 seconds, 10-30 seconds, 15-30 seconds, 1-30 seconds, 0-30 seconds, 2-20 seconds, 2-10 seconds, 5-20 seconds, 10-20 seconds, 15-25 seconds, 5-15 seconds or 5-10 seconds; as measured by a method of neurophysiological monitoring, e.g., EEG, CFM.
  • a method of neurophysiological monitoring e.g., EEG, CFM.
  • FIG. 1 Physical appearance of ALLO formulations with Captisol.
  • FIG. Plasma exposure of allopregnanolone from human SE study. Plasma concentration profile over time of allopregnanolone in a single male patient. The patient was dosed
  • ALLO allopregnanolone
  • administered in combination or a combined administration of two agents (e.g., a neuroactive steroid and a benzodiazepine or anesthetic/sedative) means that two or more agents are administered to a subject at the same time or within an interval such that there is overlap of an effect of each agent on the patient. Preferably they are administered within 15, 10, 5, or 1 minute of one another. Preferably the administrations of the agents are spaced sufficiently close together such that a combinatorial effect is achieved.
  • the agents can be administered
  • the agents can be administered at a specified time interval, for example, an interval of minutes, hours, days or weeks. Generally, the agents are concurrently bioavailable, e.g., detectable, in the subject.
  • the agents e.g., a neuroactive steroid and a benzodiazepine or anesthetic/sedative
  • the agents are administered essentially simultaneously, for example two unit dosages administered at the same time, or a combined unit dosage of the two agents.
  • the agents are delivered in separate unit dosages.
  • the agents can be administered in any order, or as one or more preparations that includes two or more agents.
  • At least one administration of one of the agents is made within minutes, one, two, three, or four hours, or even within one or two days of the other agent, e.g., the second agent.
  • combinations can achieve synergistic results, e.g., greater than additive results, e.g., at least 20, 50, 70, or 100% greater than additive.
  • a treatment modality with a selected state e.g., being under general anesthesia
  • a second treatment modality is administered, or is present at a preselected level, e.g., a therapeutic level
  • administration of the treatment modality overlaps or occurs at the same time as, e.g., administration of a second treatment modality.
  • an amount of a compound effective to treat a disorder refers to an amount of the compound which is effective, upon single or multiple dose administration to a subject, in treating a cell, or in curing, alleviating, relieving or improving a subject with a disorder beyond that expected in the absence of such treatment.
  • GA general anesthesia
  • a subject receives medications for e.g., amnesia, analgesia, muscle paralysis, and sedation.
  • a treatment that induces deep sleep typically used so that subjects will not feel pain during surgery.
  • An anesthetized patient can be thought of as being in a reversible and controlled state of
  • GA agents can be administered intravenously or inhaled.
  • the term "subject” is intended to include human and non-human animals.
  • exemplary human subjects include a human patient having a disorder, e.g., a disorder described herein or a normal subject.
  • non-human animals of the invention includes all vertebrates, e.g., non-mammals (such as chickens, amphibians, reptiles) and mammals, such as non-human primates, domesticated and/or agriculturally useful animals, e.g., sheep, dog, cat, cow, pig, etc.
  • Neuroactive steroids are natural, synthetic, or semi- synthetic steroids that rapidly alter neuronal excitability through interaction with neuro transmitter-gated ion channels.
  • Neuroactive steroids effect binding to membrane-bound receptors such as those for inhibitory and (or) excitatory neurotransmitters including GABAA, NMD A, and sigma receptors.
  • the steroids that may be classified into functional groups according to chemical structure and physiological activity and include estrogenic hormones, progestational hormones, and androgenic hormones.
  • progestational hormones referred to herein as "progestins” or “progestogens”, and their derivatives and bioactive metabolites.
  • progestins e.g., progesterone
  • progestin metabolites such as progesterone.
  • progesterone refers to a member of the progestin family and includes a 21 carbon steroid hormone. Progesterone is also known as D4-pregnene-3,20-dione; ⁇ 4- pregnene-3,20-dione; or pregn-4-ene-3,20-dione. As used herein a “synthetic progestin” is a molecule whose structure is related to that of progesterone, is synthetically derived, and retains the biological activity of progesterone.
  • Representative synthetic progestins include, but are not limited to, substitutions at the 17- position of the progesterone ring to introduce a hydroxyl, acetyl, hydroxyl acetyl, aliphatic, nitro, or heterocyclic group, modifications to produce 17a-OH esters (e.g., 17 a-hydroxyprogesterone caproate), as well as modifications that introduce 6-methyl, 6-ene, and 6-chloro substituents onto progesterone (e.g., medroxyprogesterone acetate, megestrol acetate, and chlomadinone acetate), and which retains the biological activity of progesterone.
  • substitutions at the 17- position of the progesterone ring to introduce a hydroxyl, acetyl, hydroxyl acetyl, aliphatic, nitro, or heterocyclic group
  • modifications to produce 17a-OH esters e.g., 17 a-hydroxyprogesterone caproate
  • progestin derivatives include 5- dehydroprogesterone, 6-dehydro-retroprogesterone (dydrogesterone), allopregnanolone (allopregnan-3a, or 3 ⁇ - ⁇ 1-20- ⁇ ), ethynodiol diacetate, hydroxyprogesterone caproate (pregn-4- ene-3,20-dione, 17-(l-oxohexy)oxy); levonorgestrel, norethindrone, norethindrone acetate (19- norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-,(17a)-); norethynodrel, norgestrel, pregnenolone, and megestrol acetate.
  • Useful progestins also can include allopregnone-3 or 3 ⁇ , 20a or 20P-diol (see Merck Index 258-261); allopregnane-3p,21-diol-l l,20-dione; allopregnane-3p,17a-diol-20-one; 3,20- allopregnanedione, allopregnane, 3 ⁇ ,11 ⁇ ,17 ⁇ ,20 ⁇ ,21- ⁇ 1; allopregnane-3p,17a,20p,21-tetrol; allopregnane-3 or 3p,l ip,17a,21-tetrol-20-one, allopregnane- 3 ⁇ , 17a or 20 ⁇ - ⁇ 1; allopregnane- 3 ⁇ ,17 ⁇ ,21- ⁇ 1-11,20-dione; allopregnane-3 ⁇ ,l 1 ⁇ ,21- ⁇ 1-20- ⁇ ; allopregnane-3 ⁇ ,17 ⁇ ,21-triol-20
  • progestin derivatives include esters with non-toxic organic acids such as acetic acid, benzoic acid, maleic acid, malic acid, caproic acid, and citric acid and inorganic salts such as hydrochloride, sulfate, nitrate, bicarbonate and carbonate salts.
  • suitable progestins include alphaxalone, alphadolone, hydroxydione, and minaxolone.
  • the steroids are one or more of a series of sedative-hypnotic 3 alpha-hydroxy ring A-reduced pregnane steroids that include the major metabolites of progesterone and deoxycorticosterone, 3 alpha-hydroxy- 5 alpha-pregnan-20-one (allopregnanolone) and 3 alpha,21-dihydroxy-5 alpha-pregnan-20-one (allotetrahydroDOC), respectively.
  • These 3 alpha- hydroxysteroids do not interact with classical intracellular steroid receptors but bind
  • GABA gamma-amino-butyric acid
  • the neuroactive steroids are progesterone, allopregnanolone or other progesterone analogs.
  • the neuroactive steroid is allopregnanolone or a derivative thereof.
  • Exemplary derivatives include, but are not limited to, (20R)-17beta-(l-hydroxy- 2,3-butadienyl)-5alpha-androstane-3alpha-ol (HBAO). Additional derivatives are described in WO 2012/127176.
  • allopregnanolone also encompasses pharmaceutically acceptable, pharmacologically active derivatives including individual enantiomers (dextrogyral and levrogyral enantiomers) and their pharmaceutically acceptable salts, mixtures of enantiomers and their pharmaceutically acceptable salts, and active metabolites and their pharmaceutically acceptable salts, unless otherwise noted. It is understood that in some cases dosages of enantiomers, derivatives, and metabolites may need to be adjusted based on relative activity of the racemic mixture of
  • allopregnanolone can be formulated with a host, such as a cyclodextrin to improve the solubility.
  • allopregnanolone can be modified in an attempt to improve the solubility.
  • polar groups can be introduced onto position 16a with the goal of increasing water solubility, brain accessibility, and potency of neuroactive steroids as described in Kasal et al., J. Med. Chem., 52(7), 2119-215 (2009).
  • the compounds described herein e.g., allopregnanolone
  • An anesthetic e.g., general anesthetic
  • sedative is a drug that can bring about, induce, and maintain a reversible loss of consciousness.
  • a sedative is a substance that induces sedation by reducing irritability or excitement in a subject.
  • Intravenous injections of anesthetics are generally preferred to inhalation, intramuscular or subcutaneous injections because they are faster, generally less painful and more reliable.
  • anesthetics include propofol, etomidate, barbiturates (e.g., pentobarbital, methohexital, thiopentone/thiopental), benzodiazepines (e.g., as described herein, e.g., midazolam), and ketamine.
  • a subject that has been administered an anesthetic agent or anesthetic is under general anesthesia.
  • a benzodiazepine is a compound having a core chemical structure of a fusion of a benzene ring and a diazepine ring.
  • Benzodiazepines can enhance the effect of the neurotransmitter gamma-aminobutyric acid (GAB A) at the GABA A receptor, and can result in sedative, hypnotic (sleep-inducing), anxiolytic (antianxiety), anticonvulsant, or muscle relaxant properties.
  • GABA A neurotransmitter gamma-aminobutyric acid
  • Benzodiazepines are categorized as either short-, intermediate- or long-acting.
  • Exemplary benzodiazapines include alprazolam, bretazenil, bromazepam, brotizolam, chloridazepoxide, cinolazepam, clonazepam, chorazepate, clotiazepam, cloxazolam, delorazepam, diazepam, estazolam, etizolam, ethyl loflazepate, flunitrazepam, flurazepam, flutoprazepam, halazepam, ketazolam, loprazolam, lorazepam, lormetazepam, medazepam, midazolam, nimetazepam, nitrazepam, nordazepam, oxazepam, phenazepam, pinazepam, prazepam, premazepam, pyrazolam, quazepam, temaze
  • a commonly used anesthetic agent is midazolam.
  • the benzodiazepine is midazolam.
  • Barbiturates are drugs that have been used as CNS depressants and used e.g., to induce mild sedation, total anesthesia; and used as an anxiolytic, hypnotic, anticonvulsant, analgesic. Side effects of barbiturates include addiction potential, e.g., physical and psychological addiction.
  • Barbiturates may be classified as e.g., ultrashort- acting, short/intermediate-acting, and long-acting.
  • Exemplary barbiturates include pentobarbital, allobarbital, amobarbital, aprobarbital, barbital, brallobarbital.
  • Propofol (2,6-diisopropylphenol) is a drug, administered intravenously, that provides loss of awareness and can be used with other general anesthetic agents.
  • the main advantages are favorable operating conditions and rapid recovery, but have disadvantages that include a relatively high incidence of apnea and blood pressure reductions.
  • neuroactive steroid also encompasses pharmaceutically acceptable, pharmacologically active derivatives of these agents (e.g., neuroactive steroids including both individual enantiomers of neuroactive steroids (dextrogyral and levrogyral enantiomers)) and their pharmaceutically acceptable salts, mixtures of enantiomers and their pharmaceutically acceptable salts, and active metabolites and their pharmaceutically acceptable salts, unless otherwise noted. It is understood that in some cases dosages of enantiomers, derivatives, and metabolites may need to be adjusted based on relative activity of the racemic mixture.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making the acid-addition or base-addition salts thereof.
  • Example of pharmaceutically acceptable salts include but are not limited to mineral or organic acid salts of basic residues such as amines; and alkali or organic salts of acidic residues such as carboxylic acids.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • Such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric acids; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, tolunesulfonic, naphthalenesulfonic, methanesulfonic, ethane disulfonic, oxalic, and isethionic salts.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric acids
  • organic acids such as acetic, propionic, succinic, glycolic, ste
  • the pharmaceutically acceptable salts of the compounds can be synthesized from the parent compound, which contains a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 20th ed., Lippincott Williams & Wilkins, Baltimore, MD, 2000, p. 704.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.
  • Stereoisomers described herein such as neuroactive steroids, generally contain one or more chiral centers, and thus exist as one or more stereoisomers. Such stereoisomers can be prepared and/or isolated as a single enantiomer, a mixture of diastereomers, or a racemic mixture.
  • stereoisomers refers to compounds made up of the same atoms having the same bond order but having different three-dimensional arrangements of atoms which are not interchangeable. The three-dimensional structures are called configurations.
  • enantiomers refers to two stereoisomers which are non-superimposable mirror images of one another.
  • optical isomer is equivalent to the term “enantiomer”.
  • diastereomer refers to two stereoisomers which are not mirror images but also not superimposable.
  • racemate racemic mixture” or “racemic modification” refer to a mixture of equal parts of enantiomers.
  • chiral center refers to a carbon atom to which four different groups are attached.
  • Choice of the appropriate chiral column, eluent, and conditions necessary to effect separation of the pair of enantiomers is well known to one of ordinary skill in the art using standard techniques (see e.g. Jacques, J. et al., “Enantiomers, Racemates, and Resolutions", John Wiley and Sons, Inc. 1981).
  • compositions described herein include a therapeutically effective amount of a neuroactive steroid, such as allopregnanolone, and a therapeutically effective amount of a benzodiazepine or anesthetic/sedative.
  • the neuroactive steroid and benzodiazepine or anesthetic/sedative are co-formulated into a single composition or dosage.
  • the neuroactive steroid and benzodiazepine or anesthetic/sedative are administered separately.
  • the neuroactive steroid and benzodiazepine or anesthetic/sedative are administered sequentially.
  • the neuroactive steroid and benzodiazepine or anesthetic/sedative are administered separately and sequentially.
  • at least one of the neuroactive steroid and benzodiazepine or anesthetic/sedative is administered parenterally (e.g., intranasally, buccally, intravenously or intramuscularly, for example,
  • both the neuroactive steroid and benzodiazepine or anesthetic/sedative is administered parenterally (e.g., intranasally, buccally, intravenously or intramuscularly).
  • the neuroactive steroid and/or the benzodiazepine or anesthetic/sedative is administered in a dose equivalent to parenteral administration of about 0.1 ng to about 100 g per kg of body weight, about 10 ng to about 50 g per kg of body weight, about 100 ng to about 1 g per kg of body weight, from about ⁇ ⁇ to about 100 mg per kg of body weight, from about 10 ⁇ g to about 10 mg per kg of body weight, from about 100 ⁇ g to about 5 mg per kg of body weight, from about 250 ⁇ g to about 3 mg per kg of body weight, from about 500 ⁇ g to about 2 mg per kg of body weight, from about 1 ⁇ g to about 50 mg per kg of body weight, from about 1 ⁇ g to about 500 ⁇ g per kg of body weight; and from about 1 ⁇ g to about 50 ⁇ g per kg of body weight.
  • the amount of neuroactive steroid and/or the benzodiazepine or anesthetic/sedative administered to achieve a therapeutic effective dose is about 0.1 ng, 1 ng, 10 ng, 100 ng, 1 ⁇ g, 10 ⁇ g, 100 ⁇ g, 1 mg, 1.5mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 500 mg per kg of body weight or greater.
  • the neuroactive steroid is administered as an intravenous bolus infusion in a dose equivalent to parenteral administration of about 0.1 ng to about 100 g per kg of body weight, about 10 ng to about 50 g per kg of body weight, about 100 ng to about 1 g per kg of body weight, from about ⁇ g to about 100 mg per kg of body weight, from about 1 ⁇ g to about 50 mg per kg of body weight, from about 10 ⁇ g to about 5 mg per kg of body weight, from about 100 ⁇ g to about 500 ⁇ g per kg of body weight, from about 100 ⁇ g to about 400 ⁇ g per kg of body weight, from about 150 ⁇ g to about 350 ⁇ g per kg of body weight, from about 250 ⁇ g to about 300 ⁇ g per kg of body weight.
  • the neuroactive steroid is administered as an intravenous bolus infusion in a dose equivalent to parenteral administration of about 100 to about 400 ⁇ g/kg. In some embodiments, the neuroactive steroid is administered as an intravenous bolus infusion at about 150 to about 350 ⁇ g/kg. In some embodiments, the neuroactive steroid is administered as an intravenous bolus infusion at about 250 to about 300 ⁇ g/kg.
  • the neuroactive steroid is administered as an intravenous bolus infusion in a dose equivalent to about 100 ⁇ g/kg, 125 ⁇ g/kg , 150 175 200 290 ⁇ g/kg, 300 ⁇ g/kg, 325 ⁇ g/kg, or 350 ⁇ g/kg.
  • the neuroactive steroid is administered as an intravenous bolus infusion in a dose equivalent to parenteral administration of about 0.1 nmoles/L to about 100 per kg of body weight, about 1 nmoles/L to about 10 per kg of body weight, about 10 nmoles/L to about 10 per kg of body weight, about 100 nmoles/L to about 10 per kg of body weight, about 300 nmoles/L to about 5 per kg of body weight, about 500 nmoles/L to about 5 per kg of body weight, and about 750 nmoles/L to about 1 per kg of body weight,
  • the amount of neuroactive steroid administered to achieve a therapeutic effective dose is about 0.1 ng, 1 ng, 10 ng, 100 ng, 1 ⁇ g, 10 ⁇ g, 100 ⁇ g, 1 mg, 1.5mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg,
  • anesthetic/sedative may be administered once or several times a day.
  • a duration of treatment may follow, for example, once per day for a period of about 1, 2, 3, 4, 5, 6, 7 days or more.
  • either a single dose in the form of an individual dosage unit or several smaller dosage units or by multiple administration of subdivided dosages at certain intervals is administered.
  • a dosage unit can be administered from about 0 hours to about 1 hr, about 1 hr to about 24 hr, about 1 to about 72 hours, about 1 to about 120 hours, or about 24 hours to at least about 120 hours post injury.
  • the dosage unit can be administered from about 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 30, 40, 48, 72, 96, 120 hours or longer post injury.
  • Subsequent dosage units can be administered any time following the initial administration such that a therapeutic effect is achieved.
  • additional dosage units can be administered to protect the subject from the secondary wave of edema that may occur over the first several days post-injury.
  • AUC Area under the curve
  • benzodiazepine standard or “anesthetic/sedative standard” is intended the formulation of neuroactive steroid or the benzodiazepine or anesthetic/sedative that serves as the basis for determination of the total hourly neuroactive steroid and/or the benzodiazepine or
  • anesthetic/sedative dose to be administered to a human subject with epilepsy or status epilepticus to achieve the desired positive effect, i.e., a positive therapeutic response that is improved with respect to that observed without administration of neuroactive steroid and/or the benzodiazepine or anesthetic/sedative.
  • the dose of neuroactive steroid and/or the benzodiazepine or anesthetic/sedative to be administered provides a final serum level of neuroactive steroid and/or the benzodiazepine or anesthetic/sedative of about 100 ng/mL to about 1000 ng/mL, about 1100 ng/mL to about 1450 ng/mL, 100 ng/mL to about 250 ng/mL, about 200 ng/mL to about 350 ng/mL, about 300 ng/mL to about 450 ng/mL, about 350 ng/mL to about 450 ng/mL, about 400 ng/mL to about 550 ng/mL, about 500 ng/mL to about 650 ng/mL, about 600 ng/mL to about 750 ng/mL, about 700 ng/mL to about 850 ng/mL, about 800 ng/mL to about 950 ng/mL, about 900 ng/m
  • the serum level of neuroactive steroid and/or the benzodiazepine or anesthetic/ sedative is about 100 ng/mL, 250 ng/mL, 300 ng/mL, 350 ng/mL, 360 ng/mL, 370 ng/mL, 380 ng/mL, 390 ng/mL, 400 ng/mL, 410 ng/mL, 420 ng/mL, 430 ng/mL, 440 ng/mL, 450 ng/mL, 500 ng/mL, 750 ng/mL, 900 ng/mL, 1200 ng/mL, 1400 ng/mL, or 1600 ng/mL.
  • the dose of neuroactive steroid to be administered provides a final serum level of neuroactive steroid of about 100 nmoles/L to about 5000 nmoles/L, about 100 nmoles/L to about 2500 nmoles/L, about 100 nmoles/L to about 1000 nmoles/L, 100 nmoles/L to about 500 nmoles/L, about 100 nmoles/L to about 250 nmoles/L, about 100 nmoles/L to about 200 nmoles/L, about 125 nmoles/L to about 175 nmoles/L. or about 140 nmoles/L to about 160 nmoles/L.
  • the serum level of neuroactive steroid and/or the benzodiazepine or anesthetic/sedative is about 100 nmoles/L, 125 nmoles/L, 150 nmoles/L, 175 nmoles/L, 200 nmoles/L, 250 nmoles/L, 300 nmoles/L, 350 nmoles/L, 500 nmoles/L, 750 nmoles/L, 1000 nmoles/L, 1500 nmoles/L, 2000 nmoles/L, 2500 nmoles/L, or 5000 nmoles/L.
  • the neuroactive steroid and the benzodiazepine or anesthetic/sedative administration includes a time period in which the administration of the benzodiazepine therapy or anesthetic/sedative is weaned off.
  • weaning or “weaning dose” refers to an administration protocol which reduces the dose of administration to the patient and thereby produces a gradual reduction and eventual elimination of the benzodiazepine or anesthetic/sedative, either over a fixed period of time or a time determined empirically by a physician's assessment based on regular monitoring of a therapeutic response of a subject.
  • the period of the weaned benzodiazepine or anesthetic/sedative administration can be about 12, 24, 36, 48 hours or longer.
  • the period of the weaned benzodiazepine or anesthetic/sedative administration can range from about 1 to 12 hours, about 12 to about 48 hours, or about 24 to about 36 hours. In some embodiments, the period of the weaned benzodiazepine or anesthetic/sedative administration is about 24 hours.
  • the weaning employed could be a "linear” weaning.
  • a " 10%” linear weaning from 500 mg would go 500, 450, 400, 350, 300, 250, 200, 150, 100, 50.
  • an exponential weaning could be employed which, if the program outlined above is used as an example, the exponential weaning would be, e.g., 500, 450, 405, 365, 329, 296, 266, 239, etc. Accordingly, about a 5%, 10%, 15%, 20%, 25%, 30%, 35%, or 40% linear or exponential weaning could be employed in the methods of the invention.
  • a linear or exponential weaning of about 1% to 5%, about 6% to 10%, about 11 % to 15%, about 16% to 20%, about 21% to 25%, about 26% to 30%, about 31% to 35%, about 36% to 40% could be employed.
  • the neuroactive steroid and the benzodiazepine or anesthetic/sedative administration includes a final time period in which the administration of neuroactive steroid is tapered off.
  • tapeered administration refers to an administration protocol which reduces the dose of administration to the patient and thereby produces a gradual reduction and eventual elimination of neuroactive steroid, either over a fixed period of time or a time determined empirically by a physician's assessment based on regular monitoring of a therapeutic response of a subject.
  • the period of the tapered neuroactive steroid administration can be about 12, 24, 36, 48 hours or longer.
  • the period of the tapered neuroactive steroid administration can range from about 1 to 12 hours, about 12 to about 48 hours, or about 24 to about 36 hours. In some embodiments, the period of the tapered neuroactive steroid administration is about 24 hours.
  • the drug taper employed could be a "linear" taper.
  • a " 10%” linear taper from 500 mg would go 500, 450, 400, 350, 300, 250, 200, 150, 100, 50.
  • an exponential taper could be employed which, if the program outlined above is used as an example, the exponential taper would be, e.g., 500, 450, 405, 365, 329, 296, 266, 239, etc. Accordingly, about a 5%, 10%, 15%, 20%, 25%, 30%, 35%, or 40% linear or exponential taper could be employed in the methods of the invention.
  • a linear or exponential taper of about 1% to 5%, about 6% to 10%, about 11 % to 15%, about 16% to 20%, about 21% to 25%, about 26% to 30%, about 31% to 35%, about 36% to 40% could be employed.
  • the drug taper is a about 25% linear taper.
  • a subject undergoing therapy exhibits a partial response, or a relapse following completion of the first cycle of the therapy
  • subsequent courses of neuroactive steroid therapy may be needed to achieve a partial or complete therapeutic response.
  • a subject may receive one or more additional treatment periods including either constant or two-level neuroactive steroid and/or the benzodiazepine or anesthetic/sedative dosing regimens.
  • Such a period of time off between treatment periods is referred to herein as a time period of discontinuance. It is recognized that the length of the time period of discontinuance is dependent upon the degree of subject response (i.e., complete versus partial) achieved with any prior treatment periods of the neuroactive steroid..
  • the neuroactive steroid is administered as an intravenous infusion for about 5 minutes to about 1 week; about 30 minutes to about 24 hours, about 1 hour to about 12 hours, about 2 hours to about 12 hours, about 4 hours to about 12 hours, about 6 hours to about 12 hours, about 6 hours to about 10 hours; about 5 minutes to about 1 hour, about 5 minutes to about 30 minutes; about 12 hours to about 1 week, about 24 hours to about 1 week, about 2 days to about 5 days, or about 3 days to about 5 days.
  • the neuroactive steroid is administered as an intravenous infusion for about 5, 10, 15, 30, 45, or 60 minutes or longer; about 1, 2, 4, 6, 8, 10, 12, 16, or 24 hours or longer; about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days or longer.
  • maintenance cycles include a completed constant or two-level neuroactive steroid or the
  • benzodiazapine dosing regimen completed two-level progesterone, allopregnanolone, or a synthetic progestin dosing regimen.
  • completed two-level progesterone, allopregnanolone, or a synthetic progestin dosing regimen is intended the subject has been administered both the first period and the second period of neuroactive steroid or the benzodiazapine dosing.
  • the necessity for multiple maintenance cycles can be assessed by monitoring the physiological and behavioral improvement of the patient.
  • the duration between maintenance cycles can be about 1 hr, 15 hr, 1 day, 2 day, 3 day, 4 day, 5 day, 6 day or other such time periods falling within the range of about 1 day to about 14 days.
  • the maintenance cycle is about 2 days. In some embodiments, the maintenance cycle is about 3 days. In some embodiments, the maintenance cycle is about 4 days. In some embodiments, the maintenance cycle is about 5 days.
  • the maintenance cycle begins from about 30 minutes to about 24 hours, about 30 minutes to about 12 hours, about 30 minutes to about 8 hours, about 30 minutes to about 4 hours, about 30 minutes to about 2 hours, about 30 minutes to about 1 hour following the initial bolus infusion administration. In some embodiments, the maintenance cycle begins 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, or longer following the initial bolus infusion administration.
  • the maintenance cycle the neuroactive steroid is administered as an intravenous infusion at an amount of neuroactive steroid/unit time of about 20 to about 5000 ⁇ g/kg/hr. In some embodiments, the maintenance cycle the neuroactive steroid is administered as an intravenous infusion at an amount of neuroactive steroid/unit time of about 20 to about 2500 ⁇ g/kg/hr. In some embodiments, the maintenance cycle the neuroactive steroid is administered as an intravenous infusion at an amount of neuroactive steroid/unit time of about 20 to about 500 ⁇ g/kg/hr. In some embodiments, the neuroactive steroid is administered as an intravenous infusion at a rate of about 20 to about 250 ⁇ g/kg/hr.
  • the neuroactive steroid is administered as an intravenous infusion at an amount of neuroactive steroid/unit time of about 20 to about 200 ⁇ g/kg/hr. In some embodiments, the neuroactive steroid is administered as an intravenous infusion at an amount of neuroactive steroid/unit time of about 20 to about 150 ⁇ g/kg/hr. In some embodiments, the neuroactive steroid is administered as an intravenous infusion at an amount of neuroactive steroid/unit time of about 50 to about 100 ⁇ g/kg/hr. In some embodiments, the neuroactive steroid is administered as an intravenous infusion at an amount of neuroactive steroid/unit time of about 70 to about 100 ⁇ g/kg/hr.
  • the neuroactive steroid is administered as an intravenous infusion at an amount of neuroactive steroid/unit time of about 25 ⁇ g/kg/hr, 50 ⁇ g/kg/hr , 75 ⁇ g/kg/hr, 80 ⁇ g/kg/hr, 85 ⁇ g/kg/hr, 86 ⁇ g/kg/hr, 87 ⁇ g/kg/hr, 88 ⁇ g/kg/hr, 89 ⁇ g/kg/hr, 90 ⁇ g/kg/hr, 100 ⁇ g/kg/hr, 125 ⁇ g/kg/hr, 150 ⁇ g/kg/hr, or 200 ⁇ g/kg/hr.
  • the neuroactive steroid is administered as an intravenous infusion in a dose equivalent to parenteral administration of about 0.1 ng to about 100 g per kg of body weight, about 10 ng to about 50 g per kg of body weight, about 100 ng to about 1 g per kg of body weight, from about ⁇ g to about 100 mg per kg of body weight, from about 1 ⁇ g to about 50 mg per kg of body weight, from about 10 ⁇ g to about 5 mg per kg of body weight; and from about 100 ⁇ g to about 1000 ⁇ g per kg of body weight.
  • the neuroactive steroid is administered as an intravenous infusion in a dose equivalent to parenteral administration of about 0.1 nmoles/L to about 100 per kg of body weight, about 1 nmoles/L to about 10 per kg of body weight, about 10 nmoles/L to about 10 per kg of body weight, about 100 nmoles/L to about 10 per kg of body weight, about 300 nmoles/L to about 5 per kg of body weight, about 500 nmoles/L to about 5 per kg of body weight, and about 750 nmoles/L to about 5 per kg of body weight,
  • the amount of neuroactive steroid administered to achieve a therapeutic effective dose is about 0.1 ng, 1 ng, 10 ng, 100 ng, 1 ⁇ g, 10 ⁇ g, 100 ⁇ -g, 1 mg, 1.5mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg
  • Formulations described herein include a neuroactive steroid and/or a benzodiazepine or anesthetic/sedative in combination with one or more pharmaceutically acceptable excipients.
  • a formulation includes both a neuroactive steroid and a benzodiazepine or anesthetic/sedative.
  • Matrix forming materials are materials which form strong, viscous gels upon hydration and provide control of drug diffusion and release. In hydrophilic matrix systems, matrix forming materials are uniformly incorporated throughout the tablet. Upon contact with water, the outer tablet layer is partially hydrated, forming a gel layer. The rate of diffusion of the drug(s) out of the gel layer and the rate of erosion of the gel layer determine overall tablet dissolution and drug delivery rates.
  • matrix forming materials include cellulose ethers that are water-soluble such as methylcellulose, ethyl cellulose and hydroxypropyl methylcellulose.
  • solubilized formulations capable of delivering therapeutically effective dosages
  • a variety of methods can be employed to enhance the solubility and bioavailability of neuroactive steroids. See, for example, "Water- Insoluble Drug Formulation", 2nd Edition, edited by Rong Liu (CRC Press, Boca Raton, FL, 2008).
  • a solubilized formulation of one or more neuroactive steroids can be prepared. These solubilized formulations can be further incorporated into the parenteral and non-parenteral formulations described in sections 2 and 3.
  • the solubility of neuroactive steroids can be improved by inclusion complexation (e.g., host- guest formulations).
  • Inclusion complexes are formed when a nonpolar molecule (i.e., the guest, such as a drug with poor aqueous stability) or portion of a molecule inserts into a nonpolar cavity of another molecule or group of molecules (i.e., the host). If the host molecule or molecules exhibit water good solubility, the solubility of the host-guest complex will be greater than the solubility of the guest alone.
  • Inclusion complexes containing or comprising one or more neuroactive steroids can be formed using any suitable host molecule or molecules.
  • the water solubility of neuroactive steroids can be increased by inclusion complexation with cyclodextrins.
  • Steroid- cyclodextrin complexes are known in the art. See, for example, U.S. Patent No. 7,569,557 to Backensfeld, et al. , and U.S. Patent Application Publication No. US 2006/0058262 to Zoppetti, et al.
  • Dextrans are soluble polysaccharides produced by bacteria and yeasts. They are characterized by a predominance (>95 ) of a (1-6) backbone linkages and varying proportions of a(l-2), a(l- 3) and a(l-4) linkages typically at branch points 1, 2. Dextrins are partially hydrolyzed glucose homopolymers composed exclusively of a(l-4) backbone linkages.
  • Cyclodextrins are cyclic oligosaccharides containing or comprising six (a-cyclodextrin), seven ( ⁇ -cyclodextrin), eight ( ⁇ -cyclodextrin), or more a-(l,4)- linked glucose residues.
  • the hydroxyl groups of the cyclodextrins are oriented to the outside of the ring while the glucosidic oxygen and two rings of the non-exchangeable hydrogen atoms are directed towards the interior of the cavity.
  • cyclodextrins possess a hydrophobic inner cavity combined with a hydrophilic exterior which conveys water solubility.
  • the neuroactive steroid i.e., the guest
  • the hydrophobic interior of the cyclodextrin i.e., the host
  • the host-guest complex retains water solubility as a consequence of the hydrophobic exterior of the cyclodextrin ring.
  • Neuroactive steroid-cyclodextrin complexes can, as solubility permits, be incorporated into any of the parenteral and non-parenteral formulations described below. If desired, the aqueous solubility of solid neuoractive steroid-cyclodextrin complexes can be further enhanced by isolating the neuoractive steroid-cyclodextrin complex as a solid via lyophilization and/or via micronizing solid neuoractive steroid-cyclodextrin complex.
  • This cyclic orientation provides a truncated cone structure that is hydrophilic on the exterior and lipophilic on the interior. Cyclodextrin complexes are formed when a guest molecule is partially or fully contained in the interior of the cavity.
  • the parent ⁇ -, ⁇ -, and ⁇ -cyclodextrins (particularly ⁇ ) have limited aqueous solubility and show toxicity when given parenterally. Therefore, the parent cyclodextrin structure can be chemically modified to generate a parenterally safe CD-derivative. The modifications are typically made at one or more of the 2, 3, or 6 position hydroxyls.
  • Neuroactive steroid-cyclodextrin complexes are preferably formed from a cyclodextrin selected from the group consisting of a-cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin, and derivatives thereof.
  • the cyclodextrin may be chemically modified such that some or all of the primary or secondary hydroxyl groups of the macrocycle, or both, are functionalized with a pendant group.
  • Suitable pendant groups include, but are not limited to, sulfinyl, sulfonyl, phosphate, acyl, and Q- C 12 alkyl groups optionally substituted with one or more (e.g., 1, 2, 3, or 4) hydroxy, carboxy, carbonyl, acyl, oxy, oxo; or a combination thereof.
  • Methods of modifying these alcohol residues are known in the art, and many cyclodextrin derivatives are commercially available, including sulfo butyl ether ⁇ -cyclodextrins available under the trade name CAPTISOL® from Ligand
  • Suitable cyclodextrins for use in neuroactive steroid can include cyclodextrins disclosed in U.S. Patent Nos. 5,874,418; 6,046, 177; and 7,635,733, which are herein incorporated by reference.
  • Suitable cyclodextrins for use in neuroactive steroid formulations non-exclusively include a-cyclodextrin; ⁇ -cyclodextrin; ⁇ - cyclodextrin; methyl a-cyclodextrin; methyl ⁇ -cyclodextrin; methyl ⁇ -cyclodextrin; ethyl ⁇ - cyclodextrin; butyl a-cyclodextrin; butyl ⁇ -cyclodextrin; butyl ⁇ -cyclodextrin; pentyl ⁇ -cyclodextrin; hydroxyethyl ⁇ -cyclodextrin; hydroxyethyl ⁇ -cyclodextrin; 2-hydroxypropyl a-cyclodextrin; 2- hydroxypropyl ⁇ -cyclodextrin; 2-hydroxypropyl ⁇ -cyclodextrin; 2-hydroxybutyl ⁇ -cyclodextrin
  • carboxymethylether carboxymethylethyl ⁇ -cyclodextrin; phosphate ester ⁇ -cyclodextrin; phosphate ester ⁇ -cyclodextrin; phosphate ester ⁇ -cyclodextrin; 3-trimethylammonium-2-hydroxypropyl ⁇ - cyclodextrin; sulfobutyl ether ⁇ -cyclodextrin; carboxymethyl ⁇ -cyclodextrin; carboxymethyl ⁇ - cyclodextrin; carboxymethyl ⁇ -cyclodextrin; carboxymethyl ⁇ -cyclodextrin, and combinations thereof.
  • Preferred cyclodextrins include, but are not limited to, alkyl cyclodextrins, hydroxy alkyl cyclodextrins, such as hydroxy propyl ⁇ -cyclodextrin, carboxy alkyl cyclodextrins and sulfoalkyl ether cyclodextrins, such as sulfo butyl ether ⁇ -cyclodextrin.
  • the cyclodextrin is a alpha, beta, or gamma cyclodextrin having a plurality of charges (e.g., negative or positive) on the surface.
  • the cyclodextrin is a ⁇ -cyclodextrin containing or comprising a plurality of functional groups that are negatively charged at physiological pH. Examples of such functional groups include, but are not limited to, carboxylic acid (carboxylate) groups, sulfonate (RSO 3 ), phosphonate groups, phosphinate groups, and amino acids that are negatively charged at physiological pH.
  • the charged functional groups can be bound directly to the cyclodextrins or can be linked by a spacer, such as an alkylene chain.
  • the number of carbon atoms in the alkylene chain can be varied, but is generally between about 1 and 10 carbons, preferably 1-6 carbons, more preferably 1-4 carbons.
  • Highly sulfated cyclodextrins are described in U.S. Patent No. 6,316,613.
  • the cyclodextrins is a ⁇ -cyclodextrin functionalized with a plurality of sulfobutyl ether groups.
  • a cyclodextrins is sold under the trade name CAPTISOL®.
  • CAPTISOL® is a polyanionic beta-cyclodextrin derivative with a sodium sulfonate salt separated from the lipophilic cavity by a butyl ether spacer group, or sulfobutylether (SBE).
  • CAPTISOL® is not a single chemical species, but comprised of a multitude of polymeric structures of varying degrees of substitution and positional/regional isomers dictated and controlled to a uniform pattern by a patented manufacturing process consistently practiced and improved to control impurities.
  • CAPTISOL ® contains six to seven sulfobutyl ether groups per cyclodextrin molecule.
  • CAPTISOL ® Because of the very low pKa of the sulfonic acid groups, CAPTISOL ® carries multiple negative charges at physiologically compatible pH values. The four-carbon butyl chain coupled with repulsion of the end group negative charges allows for an "extension" of the cyclodextrin cavity. This often results in stronger binding to drug candidates than can be achieved using other modified cyclodextrins. It also provides a potential for ionic charge interactions between the cyclodextrin and a positively charged drug molecule. In addition, these derivatives impart exceptional solubility and parenteral safety to the molecule. Relative to beta-cyclodextrin, CAPTISOL® provides higher interaction characteristics and superior water solubility in excess of 100 grams/100 ml, a 50-fold improvement.
  • the cyclodextrins has plurality of functional groups that are negatively charged at physiological pH. Suitable positively charged groups include, but are not limited to, quaternary ammonium groups. Exemplary cyclodextrins include, but are not limited to, mono-6(A)- butylammonium-6(A)-deoxy-beta-cyclodextrin tosylate (BuAM-beta-CD) and Amine- and guanidine- derivatised ⁇ -cyclodextrin (PCD).
  • BuAM-beta-CD mono-6(A)- butylammonium-6(A)-deoxy-beta-cyclodextrin tosylate
  • PCD Amine- and guanidine- derivatised ⁇ -cyclodextrin
  • the cyclodextrin is present in an amount of from about 0.1% to about 40% w/w of the overall formulation, preferably from about 5% to about 40% w/w, more preferably about 10% to about 40% w/w, most preferably about 10% to about 35% w/w.
  • the concentration of the cyclodextrins is from about 15% to about 35% w/w, preferably from about 20% to about 35% w/w, more preferably about 30% to about 35% w/w.
  • the formulation contains about 1 to about 2, preferably about 1.5 mg neuroactive steroid (e.g., allopregnanolone) per ml of cyclodextrin, e.g., CAPTISOL®.
  • Ion exchange resins are high molecular weight water insoluble polymers containing or comprising fixed positively or negatively charged functional groups in their matrix, which have an affinity for oppositely charged counter ions.
  • IER are solid insoluble high molecular weight poly electrolytes that can exchange with surrounding medium reversibly and stochiometrically.
  • IER are Styrene (Di Vinyl Benzene) copolymer containing or comprising
  • the IE process is known as either cation exchange (CE) or anion exchange (AE).
  • CE cation exchange
  • AE anion exchange
  • the IE process is competitive in nature.
  • drug in an ionic form usually solution
  • IER a complex
  • 'resinate' a complex
  • IER In general, IER consist of spherical beads of approximately 0.5-1.2 mm in diameter. The most common type is an opaque yellow in color, although other colors are also reported. The constitution of each spherical particle of IER is similar to that of a homogeneous gel. The shrinkage or expansion of the spherical volume that takes place is based on the ionic environment in which the IER is present.
  • Ion exchange resins offers better drug retaining properties and prevention of dose dumping.
  • the polymeric (physical) and ionic (chemical) properties of ion exchange resin will release the drugs more uniformly than that of simple matrices (because of physical properties only).
  • Drug loaded onto the strong IER resinates provides simplest form of controlled or sustained release delivery system. Resinates can be filled directly in a capsule, suspended in liquids, suspended in matrices or compressed into tablets. Drug will be slowly released by ion exchange phenomenon and absorbed.
  • Microencapsulation of resinates provides better control over the drug release for oral or depo release.
  • the absorption of the drug from coated resinates is a consequence of the entry of the counter ions into the coated resinates and release of drug ions from drug resin complex by the ion exchange process and diffusion of drug ions through the membrane into the dissolution medium.
  • Designed release rate at the desired level can be obtained by optimization of coating thickness.
  • Microencapsulation of resinates can be achieved by air suspension coating (Wurster process), interfacial polymerization, solvent evaporation or pan coating.
  • Modification of the coating of resinates for example, by pretreatment with polyethylene glycol 400, can be used to maintain the geometry and improve coating process.
  • the pretreated resinates are then coated with ethyl cellulose or any other water insoluble polymer.
  • polyethylene glycol helps in controlling the swelling rate of matrix in water, while an outer ethyl cellulose coating modifies the diffusion pattern of ions in and out of system.
  • a major drawback of controlled or sustained release systems is dose dumping, resulting in increased risk of toxicity.
  • Ion exchange resins offers better drug retaining properties and prevention of dose dumping.
  • the polymeric (physical) and ionic (chemical) properties of ion exchange resin release the drugs more uniformly than that of simple matrices.
  • Drug loaded onto the strong IER resinates provides simplest form of controlled or sustained release delivery system.
  • Resinates can be filled directly in a capsule, suspended in liquids, suspended in matrices or compressed into tablets. Drug will be slowly released by ion exchange phenomenon and absorbed.
  • lipid carriers may be used.
  • Lipid emulsions are known in the art. See, for example, U.S. Patent No. 6361792 to Long, et. al.; U.S. Patent No. 7,550,155 to Zhang, et al, and U.S. Patent Application Publication No. US 2006/0067952.
  • Lipid emulsions formulations typically include one or more neuroactive steroids, an oil component, an emulsifier, and water.
  • the oil component can be a monoglyceride, a diglyceride, a triglyceride, or combinations thereof.
  • the oil component includes an ester formed between one or more fatty acids and an alcohol other than glycerol.
  • the oil component can be, for example, a vegetable oil such as almond oil, borage oil, black currant seed oil, corn oil, safflower oil, soybean oil, sesame oil, cottonseed oil, peanut oil, olive oil, rapeseed oil, coconut oil, palm oil, canola oil, or combinations thereof.
  • Vegetable oils are typically long-chain triglycerides formed from C 14 -C22 fatty acids.
  • the oil component can also include medium chain triglycerides formed from C8-C12 fatty acids, such as Miglyol 812, Crodamol® GTCC-PN, or Neobees M-5 oil.
  • the emulsifier serves to stabilize the lipid emulsion by preventing separation of the emulsion into individual oil and aqueous phases.
  • Suitable emulsifiers include, but are not limited to, propylene glycol mono- and di-fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene fatty acid esters, polyoxyethylene-polyoxypropylene co-polymers and block copolymers, salts of fatty alcohol sulphates, sorbitan fatty acid esters, esters of polyethylene-glycol glycerol ethers, oil and wax based emulsifiers, glycerol monostearate, glycerine sorbitan fatty acid esters and phospholipids.
  • the emulsifier is a phospholipid.
  • the emulsifier is a vitamin E derivative.
  • Suitable vitamin E derivatives include, but are not limited to, ⁇ -tocopheryl oxalate, ⁇ -tocopheryl malonate, ⁇ -tocopheryl succinate, ⁇ -tocopheryl glutarate, ⁇ -tocopheryl adipate, ⁇ -tocopheryl pimelate, ⁇ -tocopheryl suberate, a- tocopheryl azelate, and D- ⁇ -tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS).
  • Exemplary phospholipids include , phosphatidyl chlorine, lecithin (a mixture of choline ester of phosphorylated diacylglyceride), phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid with about 4 to about 22 carbon atoms, and more generally from about 10 to about 18 carbon atoms and varying degrees of saturation.
  • the phospholipid is of natural origin.
  • Naturally occurring phospholipids include soy lecithin, egg lecithin, hydrogenated soy lecithin, hydrogenated egg lecithin, sphingosine, gangliosides, and phytosphingosine, and combinations thereof.
  • Suitable lipid emulsions generally contain between about 1% and 40% w/v oil component and between about 0.1% and 7.5% w/v emulsifier.
  • Suitable commercially available lipid emulsions include lipid emulsions containing or comprising soybean oil, such as Intralipid® 10%, Intralipid® 20%, and Intralipid® 30%, as well as lipid emulsions containing or comprising a mixture of soybean and safflower oils, such as Liposyn® II 10% and Liposyn® II 20%.
  • Lipid emulsions can optionally contain one or more additional components.
  • lipid formulations can contain one or more non-aqueous miscible co-solvents, such as an alcohol or glycol.
  • non-aqueous miscible co-solvents such as an alcohol or glycol.
  • glycerol and/or propylene glycol is present as a co-solvent.
  • lipid emulsions are capable of supporting bacterial growth. Accordingly, in some cases, one or more components may be added to the lipid emulsion formulation to prevent or retard bacterial growth, for example disodium edatate, citric acid, metabisulfate, benzyl alcohol, one or more parabens, chlorobutanol, phenol, sorbic acid, or thimerosal.
  • one or more components may be added to the lipid emulsion formulation to prevent or retard bacterial growth, for example disodium edatate, citric acid, metabisulfate, benzyl alcohol, one or more parabens, chlorobutanol, phenol, sorbic acid, or thimerosal.
  • lipid emulsions can contain one or more agents used to modify or stabilize the pH of the solution, including phosphate buffers, acetate buffers, and citrate buffers.
  • the formulation is an oil-in-water emulsion containing or comprising a therapeutically effective amount of one or more neuroactive steroids dissolved in a solution containing or comprising between about 1% w/v and about 25% w/v soybean oil, between about 0.5% and about 7.5% w/v egg yolk phospholipid, and between about 0.5% w/v and about 5% w/v of a miscible co- solvent.
  • the formulation is an oil-in-water emulsion containing or comprising a therapeutically effective amount of one or more neuroactive steroids dissolved in a solution containing or comprising between about 1% w/v and about 15% w/v soybean oil, between about 1% w/v and about 15% w/v safflower oil, between about 0.5% and about 7.5% w/v egg phosphatides, and between 0.5% w/v and about 5% w/v of a miscible co- solvent.
  • Lipid emulsions can be administered as described above, or incorporated into the parenteral formulations described below.
  • liposomes are generally derived from phospholipids or other lipid substances. See, for example, "Remington- The science and practice of pharmacy", 20th Edition, Jennaro et. al., (Phila,
  • Liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any nontoxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used.
  • the disclosed compositions in liposome form can contain, in addition to one or more neuroactive steroids, stabilizers, preservatives, excipients, and other suitable excipients.
  • lipids examples include the phospholipids and the phosphatidylcholines (lecithins), both natural and synthetic.
  • Methods of forming liposomes are known in the art. See, e.g., Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York p. 33 et seq., 1976.
  • the liposomes can be cationic liposomes (e.g., based on DOTMA, DOPE, DC cholesterol) or anionic liposomes. Liposomes can further comprise proteins to facilitate targeting a particular cell, if desired.
  • Administration of a composition comprising a compound and a cationic liposome can be
  • One or more neuroactive steroids can formulated using commercially available liposome preparations such as LIPOFECTIN®, LIPOFECTAMIE® (GIBCO-BRL, Inc., Gaithersburg, Md.), SUPERFECT® (Qiagen, Inc. Hilden, Germany) and TRANSFECTAM® (Promega Biotec, Inc., Madison, Wis.), as well as other liposomes developed according to procedures standard in the art. Liposomes where the diffusion of the compound or delivery of the compound from the liposome is designed for a specific rate or dosage can also be used.
  • noisy aqueous solutions of solute is enclosed by a bilayer resulting from the organization of surfactant macro molecules.
  • noisomes are used in targeted delivery of, for example, anticancer drugs, including methotrexate, doxorubicin, and immunoadjuvants. They are generally understood to be different from transferosomes, vesicles prepared from amphiphilic carbohydrate and amino group containing or comprising polymers, e.g., chitosan.
  • One or more neuroactive steroids can also be delivered using nanoerythrosomes.
  • Nanoerythrosomes are nano-vesicles made of red blood cells via dialysis through filters of defined pore size. These vesicles can be loaded with one or more neuroactive steroids.
  • Lipid nanoemulsions can also be used. Lipid nanoemulsions are known in the art. See, for example, U.S. Patent Application Publication No. US 2007/0207173 to Chen, et al, and U.S. Patent Application Publication No. US 2001/0045050 to Elbayoumi, et al. Lipid nanoemulsions can be prepared by microemulsification of any of the lipid emulsions described above using for example, a high pressure homogenizer, or via a phase inversion temperature method (PIT).
  • PIT phase inversion temperature method
  • vitamin E succinate and/or Vitamin E TPGS are included as emulsifiers.
  • the lipid nanoemulsion can further be lyophilized if desired. See, for example, U.S. Patent Publication No. US 2011/0015266.
  • Lipid anoemulsions can be administered as described above, or incorporated into the parenteral or non-parenteral formulations described below.
  • the pre-concentrate includes an oil phase which has at least one fatty acid oil.
  • Fatty acid oils of the present invention include at least one polyunsaturated fatty acid.
  • the term "polyunsaturated fatty acid” include those fatty acids having at least 50 weight percent or more of polyunsaturated fatty acids.
  • Polyunsaturated fat can be found in grain products, fish and sea food (herring, salmon, mackerel, halibut), soybeans, and fish oil.
  • Polyunsaturated fatty acids include omega-3 fatty acids and omega-6 fatty acids.
  • Polyunsaturated fatty acids include linolic acid and linolenic acid..
  • Preferable polyunsaturated fatty acids include eicosapentaenoic acid, salts of eicosapentaenoic acid, docosahexaenoic acid, salts of docosahexaenoic acid, triglycerides of eicosapentaenoic acid, triglycerides of docosahexaenoic acid, ethyl esters of eicosapentaenoic acid, or ethyl esters of docosahexaenoic acid.
  • Polyunsaturated fatty acids include omega-3 fatty acid oils and medium chain triglycerides (MCT).
  • a medium chain triglyceride contains about 6 to 14 carbon atoms, preferably about 8 to 12 carbon atoms are suitable for use in the oil phase.
  • Preferable medium chain glyceride includes, for example, caprylic/capric triglyceride such as "Migriol 810", “Migriol 812” (both trade names, manufactured by Huls Co., Ltd., available from Mitsuba Trading Co., Ltd.), a glyceryl tricaprylate (tricaprylin) such as "Panasate 800" (trade name, manufactured by NOF Corporation, Japan).
  • the pre-concentrate includes an emulsifier component.
  • the emulsifier component has one or more surfactants.
  • Surfactants include any molecule having both a polar head group, which energetically prefers solvation by water, and a hydrophobic tail that is not well solvated by water.
  • the ratio of the oil phase to the emulsifier component is important for the toxicity of the
  • Surfactants suitable for use with the pre- concentrate and emulsion include a variety of anionic and nonionic surfactants, as well as other emulsifying compounds that are capable of promoting the formation of oil-in- water emulsions; so long as they are on the GRAS (Generally Recognized as Safe) list and are approved for human consumption such as lecithin, solutol HS- 15 (polyoxyethylene esters of 12-hydroxystearic acid), polysorbate 80 or Cremophore EL (polyethoxylated castor oil). See McCutcheon's Volume 1 :
  • the compounds (e.g., allopregnanolone) described herein can be formulated for parenteral administration.
  • Preferred doses, dosage forms, or modes of administration are parenteral, e.g., intranasally, buccally, intravenous, intramuscular, subcutaneous, intraparenteral, bucosal, sublingual, intraocular, and topical (e.g., intravenous or intramuscular).
  • parenteral e.g., intranasally, buccally, intravenous, intramuscular, subcutaneous, intraparenteral, bucosal, sublingual, intraocular, and topical (e.g., intravenous or intramuscular).
  • informational material can include instructions to administer the compound described herein to a suitable subject, e.g., a human, e.g., a human having or at risk for a disorder described herein.
  • a suitable subject e.g., a human, e.g., a human having or at risk for a disorder described herein.
  • at least one of the neuroactive steroid and benzodiazepine or anesthetic/sedative is formulated for parenteral administration.
  • both the neuroactive steroid and the benzodiazepine or anesthetic/sedative are formulated for parenteral administration.
  • Parenteral formulations can be prepared as aqueous compositions using techniques known in the art.
  • such compositions can be prepared as injectable formulations, for example, solutions or suspensions; solid forms suitable for using to prepare solutions or suspensions upon the addition of a reconstitution medium prior to injection; emulsions, such as water-in-oil (w/o) emulsions, oil-in-water (o/w) emulsions, and microemulsions thereof, liposomes, or emulsomes.
  • injectable formulations for example, solutions or suspensions
  • solid forms suitable for using to prepare solutions or suspensions upon the addition of a reconstitution medium prior to injection emulsions, such as water-in-oil (w/o) emulsions, oil-in-water (o/w) emulsions, and microemulsions thereof, liposomes, or emulsomes.
  • emulsions such as water-in-oil (w/o) emulsions,
  • the parenteral formulations are prepared as an injectable formulation, e.g., for intravenous administration.
  • the parenteral formulation comprises a compound (e.g., a neurosteroid as described herein, e.g., allopregnanolone), and a cyclodextrin, e.g., a ⁇ -cyclodextrin, e.g., a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®).
  • the parenteral formulation comprises allopregnanolone and a sulfo butyl ether ⁇ -cyclodextrin, e.g., CAPTISOL®.
  • the carrier can be a solvent or dispersion medium containing or comprising, for example, water (e.g., Water for Injection, USP), ethanol, one or more polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), oils, such as vegetable oils (e.g., peanut oil, corn oil, sesame oil, etc.), and combinations thereof.
  • water e.g., Water for Injection, USP
  • ethanol e.g., ethanol
  • polyols e.g., glycerol, propylene glycol, and liquid polyethylene glycol
  • oils such as vegetable oils (e.g., peanut oil, corn oil, sesame oil, etc.), and combinations thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and/or by the use of surfactants.
  • a coating such as lecithin
  • surfactants for example, sugars or sodium chloride.
  • pharmacologically acceptable salts thereof can be prepared in water or another solvent or dispersing medium suitably mixed with one or more pharmaceutically acceptable excipients including, but not limited to, surfactants, dispersants, emulsifiers, pH modifying agents, and combination thereof.
  • Suitable surfactants may be anionic, cationic, amphoteric or nonionic surface active agents.
  • Suitable anionic surfactants include, but are not limited to, those containing or comprising carboxylate, sulfonate and sulfate ions.
  • anionic surfactants include sodium, potassium, ammonium of long chain alkyl sulfonates and alkyl aryl sulfonates such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium bis-(2-ethylthioxyl)-sulfosuccinate; and alkyl sulfates such as sodium lauryl sulfate.
  • Cationic surfactants include, but are not limited to, quaternary ammonium compounds such as benzalkonium chloride, benzethonium chloride, cetrimonium bromide, stearyl dimethylbenzyl ammonium chloride, polyoxyethylene and coconut amine.
  • nonionic surfactants include ethylene glycol monostearate, propylene glycol myristate, glyceryl monostearate, glyceryl stearate, polyglyceryl-4-oleate, sorbitan acylate, sucrose acylate, PEG- 150 laurate, PEG-400 monolaurate, polyoxyethylene monolaurate, polysorbates, polyoxyethylene octylphenylether, PEG-
  • amphoteric surfactants include sodium N-dodecyl- -alanine, sodium N-lauryl- -iminodipropionate, myristoamphoacetate, lauryl betaine and lauryl sulfobetaine.
  • the formulation can contain a preservative to prevent the growth of microorganisms.
  • Suitable preservatives include, but are not limited to, parabens, chlorobutanol, phenol, sorbic acid, and thimerosal.
  • the formulation may also contain an antioxidant to prevent degradation of the active agent(s).
  • the formulation is typically buffered to a pH of 3-8 for parenteral administration upon reconstitution.
  • Suitable buffers include, but are not limited to, phosphate buffers, acetate buffers, and citrate buffers.
  • Water soluble polymers are often used in formulations for parenteral administration.
  • Suitable water-soluble polymers include, but are not limited to, polyvinylpyrrolidone, dextran, carboxymethylcellulose, and polyethylene glycol.
  • Sterile injectable solutions can be prepared by incorporating the active compounds in the required amount in the appropriate solvent or dispersion medium with one or more of the excipients listed above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those listed above.
  • the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • the powders can be prepared in such a manner that the particles are porous in nature, which can increase dissolution of the particles. Methods for making porous particles are well known in the art.
  • At least one of the neuroactive steroid or the benzodiazepine or anesthetic/sedative is formulated for intranasal, buccal, intramuscular or intravenous administration (e.g., intramuscular or intravenous administration).
  • both of the neuroactive steroid and the benzodiazepine or anesthetic/sedative are formulated for intranasal, buccal, intramuscular or intravenous administration (e.g., intramuscular or intravenous administration).
  • parenteral formulations described herein can be formulated for controlled release including immediate release, delayed release, extended release, pulsatile release, and combinations thereof.
  • the compounds, and optionally one or more additional active agents can be incorporated into microparticles, nanoparticles, or combinations thereof that provide controlled release.
  • the formulations contains two or more drugs
  • the drugs can be formulated for the same type of controlled release (e.g., delayed, extended, immediate, or pulsatile) or the drugs can be independently formulated for different types of release (e.g., immediate and delayed, immediate and extended, delayed and extended, delayed and pulsatile, etc.).
  • the compounds and/or one or more additional active agents can be incorporated into polymeric microparticles which provide controlled release of the drug(s). Release of the drug(s) is controlled by diffusion of the drug(s) out of the microparticles and/or degradation of the polymeric particles by hydrolysis and/or enzymatic degradation.
  • Suitable polymers include ethylcellulose and other natural or synthetic cellulose derivatives.
  • Polymers which are slowly soluble and form a gel in an aqueous environment such as hydroxypropyl methylcellulose or polyethylene oxide may also be suitable as materials for drug containing or comprising microparticles.
  • Other polymers include, but are not limited to,
  • polyanhydrides poly(ester anhydrides), polyhydroxy acids, such as polylactide (PLA), polyglycolide (PGA), poly(lactide-co-glycolide) (PLGA), poly-3-hydroxybutyrate (PHB) and copolymers thereof, poly-4-hydroxybutyrate (P4HB) and copolymers thereof, polycaprolactone and copolymers thereof, and combinations thereof.
  • the drug(s) can be incorporated into microparticles prepared from materials which are insoluble in aqueous solution or slowly soluble in aqueous solution, but are capable of degrading within the GI tract by means including enzymatic degradation, surfactant action of bile acids, and/or mechanical erosion.
  • slowly soluble in water refers to materials that are not dissolved in water within a period of 30 minutes. Preferred examples include fats, fatty substances, waxes, wax-like substances and mixtures thereof.
  • Suitable fats and fatty substances include fatty alcohols (such as lauryl, myristyl stearyl, cetyl or cetostearyl alcohol), fatty acids and derivatives, including, but not limited to, fatty acid esters, fatty acid glycerides (mono-, di- and tri-glycerides), and hydrogenated fats.
  • fatty alcohols such as lauryl, myristyl stearyl, cetyl or cetostearyl alcohol
  • fatty acids and derivatives including, but not limited to, fatty acid esters, fatty acid glycerides (mono-, di- and tri-glycerides), and hydrogenated fats.
  • Specific examples include, but are not limited to hydrogenated vegetable oil, hydrogenated cottonseed oil, hydrogenated castor oil, hydrogenated oils available under the trade name Sterotex®, stearic acid, cocoa butter, and stearyl alcohol.
  • Suitable waxes and wax-like materials include natural or synthetic waxes, hydrocarbons
  • waxes include beeswax, glycowax, castor wax, carnauba wax, paraffins and candelilla wax.
  • a wax-like material is defined as any material which is normally solid at room temperature and has a melting point of from about 30 to 300°C.
  • rate-controlling (wicking) agents may be formulated along with the fats or waxes listed above.
  • rate-controlling materials include certain starch derivatives (e.g., waxy maltodextrin and drum dried corn starch), cellulose derivatives (e.g.,
  • hydroxypropylmethyl-cellulose hydroxypropylcellulose, methylcellulose, and carboxymethyl- cellulose
  • alginic acid lactose and talc.
  • a pharmaceutically acceptable surfactant for example, lecithin may be added to facilitate the degradation of such microparticles.
  • Proteins which are water insoluble can also be used as materials for the formation of drug containing or comprising microparticles.
  • proteins, polysaccharides and combinations thereof which are water soluble can be formulated with drug into microparticles and subsequently cross-linked to form an insoluble network.
  • cyclodextrins can be complexed with individual drug molecules and subsequently cross-linked.
  • Encapsulation or incorporation of drug into carrier materials to produce drug containing or comprising microparticles can be achieved through known pharmaceutical formulation techniques.
  • the carrier material is typically heated above its melting temperature and the drug is added to form a mixture comprising drug particles suspended in the carrier material, drug dissolved in the carrier material, or a mixture thereof.
  • Microparticles can be subsequently formulated through several methods including, but not limited to, the processes of congealing, extrusion, spray chilling or aqueous dispersion.
  • wax is heated above its melting temperature, drug is added, and the molten wax-drug mixture is congealed under constant stirring as the mixture cools.
  • the molten wax- drug mixture can be extruded and spheronized to form pellets or beads.
  • Detailed descriptions of these processes can be found in "Remington- The science and practice of pharmacy", 20th Edition, Jennaro et. al., (Phila, Lippencott, Williams, and Wilkens, 2000).
  • carrier materials it may be desirable to use a solvent evaporation technique to produce drug containing or comprising microparticles.
  • drug and carrier material are co- dissolved in a mutual solvent and microparticles can subsequently be produced by several techniques including, but not limited to, forming an emulsion in water or other appropriate media, spray drying or by evaporating off the solvent from the bulk solution and milling the resulting material.
  • drug in a particulate form is homogeneously dispersed in a water- insoluble or slowly water soluble material.
  • the drug powder itself may be milled to generate fine particles prior to formulation. The process of jet milling, known in the pharmaceutical art, can be used for this purpose.
  • drug in a particulate form is homogeneously dispersed in a wax or wax like substance by heating the wax or wax like substance above its melting point and adding the drug particles while stirring the mixture.
  • a pharmaceutically acceptable surfactant may be added to the mixture to facilitate the dispersion of the drug particles.
  • the particles can also be coated with one or more modified release coatings.
  • Solid esters of fatty acids which are hydrolyzed by lipases, can be spray coated onto microparticles or drug particles.
  • Zein is an example of a naturally water-insoluble protein. It can be coated onto drug containing or comprising microparticles or drug particles by spray coating or by wet granulation techniques.
  • some substrates of digestive enzymes can be treated with cross-linking procedures, resulting in the formation of non-soluble networks.
  • Many methods of cross-linking proteins initiated by both chemical and physical means, have been reported. One of the most common methods to obtain cross-linking is the use of chemical cross- linking agents.
  • Examples of chemical cross-linking agents include aldehydes (gluteraldehyde and formaldehyde), epoxy compounds, carbodiimides, and genipin.
  • aldehydes gluteraldehyde and formaldehyde
  • epoxy compounds carbodiimides
  • genipin oxidized and native sugars have been used to cross-link gelatin (Cortesi, R., et al.,
  • Cross-linking can also be accomplished using enzymatic means; for example, transglutaminase has been approved as a GRAS substance for cross-linking seafood products.
  • cross-linking can be initiated by physical means such as thermal treatment, UV irradiation and gamma irradiation.
  • a water soluble protein can be spray coated onto the microparticles and subsequently cross-linked by the one of the methods described above.
  • drug containing or comprising microparticles can be microencapsulated within protein by coacervation- phase separation (for example, by the addition of salts) and subsequently cross-linked.
  • suitable proteins for this purpose include gelatin, albumin, casein, and gluten.
  • Polysaccharides can also be cross-linked to form a water-insoluble network.
  • polysaccharides this can be accomplished by reaction with calcium salts or multivalent cations which cross-link the main polymer chains.
  • Pectin, alginate, dextran, amylose and guar gum are subject to cross-linking in the presence of multivalent cations.
  • Complexes between oppositely charged polysaccharides can also be formed; pectin and chitosan, for example, can be complexed via electrostatic interactions.
  • at least one of the neuroactive steroid and/or the benzodiazepine or anesthetic/sedative is formulated for intranasal, buccal, intramuscular or intravenous administration (e.g., intramuscular or intravenous administration).
  • both of the neuroactive steroid and the benzodiazepine or anesthetic/sedative are formulated for intranasal, buccal, intramuscular or intravenous administration (e.g., intramuscular or intravenous administration).
  • the compounds described herein can be formulated for depot injection.
  • the active agent is formulated with one or more pharmaceutically acceptable carriers that provide for the gradual release of active agent over a period of hours or days after injection.
  • the depot formulation can be administered by any suitable means; however, the depot formulation is typically administered via subcutaneous or intramuscular injection.
  • depot formulations contain one or more biodegradable polymeric or oligomeric carriers.
  • Suitable polymeric carriers include, but are not limited to poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), poly(lactic acid)- polyethyleneglycol (PLA-PEG) block copolymers, polyanhydrides, poly(ester anhydrides), polyglycolide (PGA), poly-3-hydroxybutyrate (PHB) and copolymers thereof, poly-4- hydroxybutyrate (P4HB), polycaprolactone, cellulose, hydroxypropyl methylcellulose,
  • ethylcellulose as well as blends, derivatives, copolymers, and combinations thereof.
  • the carrier and active agent can be formulated as a solution, an emulsion, or suspension.
  • One or more neuroactive steroids, and optionally one or more additional active agents, can also be incorporated into polymeric or oligomeric microparticles, nanoparticles, or combinations thereof.
  • the formulation is fluid and designed to solidify or gel (i.e., forming a hydrogel or organogel) upon injection. This can result from a change in solubility of the
  • composition upon injection, or for example, by injecting a pre-polymer mixed with an initiator and/or cross-linking agent.
  • the polymer matrix, polymer solution, or polymeric particles entrap the active agent at the injection site.
  • the active agent is released, either by diffusion of the agent out of the matrix and/or dissipation of the matrix as it is absorbed.
  • the release rate of the active agent from the injection site can be controlled by varying, for example, the chemical composition, molecular weight, crosslink density, and concentration of the polymeric carrier. Examples of such systems include those described in U.S. Pat. Nos. 4,938,763, 5,480,656 and 6,113,943.
  • Depot formulations can also be prepared by using other rate-controlling excipients, including hydrophobic materials, including acceptable oils (e.g., peanut oil, corn oil, sesame oil, cottonseed oil, etc.) and phospholipids, ion-exchange resins, and sparingly soluble carriers.
  • acceptable oils e.g., peanut oil, corn oil, sesame oil, cottonseed oil, etc.
  • phospholipids e.g., phospholipids, ion-exchange resins, and sparingly soluble carriers.
  • the depot formulation can further contain a solvent or dispersion medium containing or comprising, for example, water, ethanol, one or more polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), oils, such as vegetable oils (e.g., peanut oil, corn oil, sesame oil, etc.), and combinations thereof.
  • a solvent or dispersion medium containing or comprising, for example, water, ethanol, one or more polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), oils, such as vegetable oils (e.g., peanut oil, corn oil, sesame oil, etc.), and combinations thereof.
  • a coating such as lecithin
  • surfactants In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride.
  • Solutions and dispersions of a neuroactive steroid or a benzodiazepine or anesthetic/sedative as the free acid or base or pharmacologically acceptable salts thereof can be prepared in water or another solvent or dispersing medium suitably mixed with one or more pharmaceutically acceptable excipients including, but not limited to, surfactants, dispersants, emulsifiers, pH modifying agents, and combination thereof.
  • Suitable surfactants may be anionic, cationic, amphoteric or nonionic surface active agents.
  • Suitable anionic surfactants include, but are not limited to, those containing or comprising carboxylate, sulfonate and sulfate ions.
  • anionic surfactants include sodium, potassium, ammonium of long chain alkyl sulfonates and alkyl aryl sulfonates such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium bis-(2-ethylthioxyl)-sulfosuccinate; and alkyl sulfates such as sodium lauryl sulfate.
  • Cationic surfactants include, but are not limited to, quaternary ammonium compounds such as benzalkonium chloride, benzethonium chloride, cetrimonium bromide, stearyl dimethylbenzyl ammonium chloride, polyoxyethylene and coconut amine.
  • nonionic surfactants include ethylene glycol monostearate, propylene glycol myristate, glyceryl monostearate, glyceryl stearate, polyglyceryl-4-oleate, sorbitan acylate, sucrose acylate, PEG- 150 laurate, PEG-400 monolaurate, polyoxyethylene monolaurate, polysorbates, polyoxyethylene octylphenylether, PEG-
  • amphoteric surfactants include sodium N-dodecyl-P-alanine, sodium N-lauryl-P-iminodipropionate, myristoamphoacetate, lauryl betaine and lauryl sulfobetaine.
  • the formulation can contain a preservative to prevent the growth of microorganisms.
  • Suitable preservatives include, but are not limited to, parabens, chlorobutanol, phenol, sorbic acid, and thimerosal.
  • the formulation may also contain an antioxidant to prevent degradation of the active agent(s).
  • the formulation is typically buffered to a pH of 3-8 for parenteral administration upon reconstitution.
  • Suitable buffers include, but are not limited to, phosphate buffers, acetate buffers, and citrate buffers.
  • Water soluble polymers are often used in formulations for parenteral administration.
  • Suitable water-soluble polymers include, but are not limited to, polyvinylpyrrolidone, dextran, carboxymethylcellulose, and polyethylene glycol.
  • Sterile injectable solutions can be prepared by incorporating the active compounds in the required amount in the appropriate solvent or dispersion medium with one or more of the excipients listed above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those listed above.
  • the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • the powders can be prepared in such a manner that the particles are porous in nature, which can increase dissolution of the particles. Methods for making porous particles are well known in the art.
  • At least one of the neuroactive steroid and/or the benzodiazepine or anesthetic/sedative is formulated for intranasal, buccal, intramuscular or intravenous administration (e.g., intramuscular or intravenous administration).
  • both of the neuroactive steroid and the benzodiazepine or anesthetic/sedative are formulated for intranasal, buccal, intramuscular or intravenous administration (e.g., intramuscular or intravenous administration).
  • composition described herein can be administered adjunctively with other active compounds such as anesthetics or sedatives, e.g., benzodiazepine, e.g., midazalm, propofol, pentobarbital, and ketamine.
  • active compounds such as anesthetics or sedatives, e.g., benzodiazepine, e.g., midazalm, propofol, pentobarbital, and ketamine.
  • a composition described herein can be administered to a subject in need thereof, to treat a disorder described herein.
  • exemplary disorders include epilepsy, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super- refractory status epilepticus; non-convulsive status epilepticus, e.g., generalized status epilepticus, complex partial status epilepticus; a seizure, e.g., acute repetitive seizures, cluster seizures.
  • convulsive status epilepticus e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super- refractory status epilepticus
  • non-convulsive status epilepticus e.g., generalized status epilepticus, complex partial status epilepticus
  • a seizure e.g., acute repetitive seizures, cluster seizures.
  • a composition described herein e.g., a composition comprising allopregnanolone
  • a composition described herein is administered to a subject under general anesthesia.
  • Seizures described herein can include epileptic seizures; acute repetitive seizures; cluster seizures; continuous seizures; unremitting seizures; prolonged seizures; recurrent seizures; status epilepticus seizures, e.g., refractory convulsive status epilepticus, non-convulsive status epilepticus seizures; refractory seizures; myoclonic seizures; tonic seizures; tonic-clonic seizures; simple partial seizures; complex partial seizures; secondarily generalized seizures; atypical absence seizures; absence seizures; atonic seizures; benign Rolandic seizures; febrile seizures; emotional seizures; focal seizures; gelastic seizures; generalized onset seizures; infantile spasms; Jacksonian seizures; massive bilateral myoclonus seizures; multifocal seizures; neonatal onset seizures; nocturnal seizures; occipital lobe seizures; post traumatic seizures; subtle seizures; Sylvan seizures; visual reflex seizures; or withdrawal seizures.
  • status epilepticus seizures e.g., refractory convulsive status epilepticus, non
  • Status epilepticus encompasses a group of disorders all involving persistent or recurring seizures.
  • US United States
  • the standard of care in the United States (US) typically involves initially treating status epilepticus with a benzodiazepine as a first line agent for "early" SE.
  • IM midazolam intramuscular
  • IV lorazepam intravenous
  • RSE Refractory
  • the generally accepted course of therapy for patients in RSE is general anesthesia (GA) with an agent such as midazolam, propofol, pentobarbital, or ketamine.
  • GA general anesthesia
  • the goal of therapy with these GA agents is to induce an electroencephalographic "burst suppression" state, in an attempt to block the excitotoxic cerebral damage believed to occur as a result of continued seizure activity in the brain.
  • Burst-suppression is an electroencephalography pattern consisting of alternative periods of slow waves of high amplitude (the burst) and periods of a flat electroencephalogram (EEG) (the suppression); it is associated with comatose states of various etiologies and anesthesia (Amzica & Kroeger, 2011).
  • EEG electroencephalogram
  • the goal of a therapy is that when a patient is weaned from the general anesthesia, the patient will no longer have clinical or electrographic seizure activity.
  • EEG and EEG terminology is described in Hirsch et al., J. Clin. Neurophysiol. 2013; 30: 1- 27, which reference is incorporated in its entirety.
  • SRSE super-refractory SE
  • SE super-refractory generalized SE
  • SE can include, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus; non-convulsive status epilepticus, e.g., generalized status epilepticus, complex partial status epilepticus; generalized periodic epileptiform discharges; and periodic lateralized epileptiform discharges.
  • Convulsive status epilepticus is characterized by the presence of convulsive status epileptic seizures, and can include early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus.
  • Early status epilepticus is treated with a first line therapy.
  • Established status epilepticus is characterized by status epileptic seizures which persist despite treatment with a first line therapy, and a second line therapy is administered.
  • Refractory status epilepticus is characterized by status epileptic seizures which persist despite treatment with a first line and a second line therapy, and a general anesthetic is generally administered.
  • Super refractory status epilepticus is
  • Non-convulsive status epilepticus can include, e.g., focal non-convulsive status epilepticus, e.g., complex partial non-convulsive status epilepticus, simple partial non-convulsive status epilepticus, subtle non-convulsive status epilepticus; generalized non-convulsive status epilepticus, e.g., late onset absence non-convulsive status epilepticus, atypical absence non-convulsive status epilepticus, or typical absence non-convulsive status epilepticus.
  • focal non-convulsive status epilepticus e.g., complex partial non-convulsive status epilepticus, simple partial non-convulsive status epilepticus, subtle non-convulsive status epilepticus
  • generalized non-convulsive status epilepticus e.g., late onset absence non-convulsive status epilepticus, atypical absence non-convulsive
  • compositions described herein can also be administered as a prophylactic to a subject having a CNS disorder e.g., a traumatic brain injury, status epilepticus, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super- refractory status epilepticus; non-convulsive status epilepticus, e.g., generalized status epilepticus, complex partial status epilepticus; generalized periodic epileptiform discharges; and periodic lateralized epileptiform discharges; prior to the onset of a seizure.
  • a CNS disorder e.g., a traumatic brain injury
  • status epilepticus e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super- refractory status epileptic
  • Epilepsy is a brain disorder characterized by repeated seizures over time.
  • Types of epilepsy can include, but are not limited to generalized epilepsy, e.g., childhood absence epilepsy, juvenile nyoclonic epilepsy, epilepsy with grand-mal seizures on awakening, West syndrome, Lennox- Gastaut syndrome, partial epilepsy, e.g., temporal lobe epilepsy, frontal lobe epilepsy, benign focal epilepsy of childhood.
  • the haze appears as a "gradient" to the concentration of the ALLO.
  • a physician at the Massachusetts General Hospital, Boston, MA treated one patient in SRSE with allopregnanolone in a hydroxyl-propyl beta cyclodextrin formulation.
  • the patient was a 23- year-old, previously-healthy, male, college graduate who was started on allopregnanolone on his 92 nd day of SRSE.
  • Prior to starting allopregnanolone the patient had an extensive workup, including brain biopsy, for the cause of the SE; the workup was negative and the cause of his seizure activity was yet to be determined.
  • the pentobarbital was tapered and discontinued over the first 36 hours of allopregnanolone therapy.
  • the EEG had begun to normalize.
  • the EEG continued to improve and at 72 hours the patient was awake and followed simple midline commands. He continued to improve and was conversant, making jokes, and in a rehabilitation facility as of April 2013. There were no adverse events attributed to allopregnanolone .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Fire-Extinguishing Compositions (AREA)
  • Gasification And Melting Of Waste (AREA)
PCT/US2013/056062 2012-08-21 2013-08-21 Methods of treating epilepsy or tatus epilepticus Ceased WO2014031792A2 (en)

Priority Applications (35)

Application Number Priority Date Filing Date Title
AU2013305767A AU2013305767B2 (en) 2012-08-21 2013-08-21 Methods of treating epilepsy or status epilepticus
RS20211597A RS62761B1 (sr) 2012-08-21 2013-08-21 Alopregnanolon za lečenje refraktornog epileptičkog statusa
IL304912A IL304912A (en) 2012-08-21 2013-08-21 Treatment methods for epilepsy and status epilepticus
KR1020157007115A KR102121633B1 (ko) 2012-08-21 2013-08-21 간질 또는 간질지속 상태를 치료하는 방법
NZ705410A NZ705410A (en) 2012-08-21 2013-08-21 Methods of treating epilepsy or status epilepticus
BR112015003747A BR112015003747A2 (pt) 2012-08-21 2013-08-21 métodos de tratamento de epilepsia ou estado de mal epiléptico
CA2882708A CA2882708A1 (en) 2012-08-21 2013-08-21 Methods of treating epilepsy or status epilepticus
HRP20220005TT HRP20220005T1 (hr) 2012-08-21 2013-08-21 Alopregnanolon za liječenje refraktornog epileptičnog statusa
PL13830765T PL2887944T3 (pl) 2012-08-21 2013-08-21 Allopregnanolon do leczenia lekoopornego stanu padaczkowego
EP21200457.6A EP3957309A1 (en) 2012-08-21 2013-08-21 Preparation of a composition comprising allopregnanolone and sulfobutylether-beta-cyclodextrin
EP13830765.7A EP2887944B1 (en) 2012-08-21 2013-08-21 Allopregnanolone for treating refractory status epilepticus
SM20220006T SMT202200006T1 (it) 2012-08-21 2013-08-21 Allopregnanolone per il trattamento dello stato epilettico refrattario
JP2015528638A JP6355633B2 (ja) 2012-08-21 2013-08-21 てんかんまたはてんかん重積状態の処置方法
SG11201501911RA SG11201501911RA (en) 2012-08-21 2013-08-21 Methods of treating epilepsy or status epilepticus
CN201380053788.6A CN104736159A (zh) 2012-08-21 2013-08-21 治疗癫痫或癫痫持续状态的方法
BR122021022560-5A BR122021022560B1 (pt) 2012-08-21 2013-08-21 Kit, método de preparação de dosagens e método de ajuste da quantidade de diluentes e ou alopregnanolona em dispositivo de liberação
SI201331956T SI2887944T1 (sl) 2012-08-21 2013-08-21 Alopregnanolon za zdravljenje refraktornega epileptičnega statusa
LTEPPCT/US2013/056062T LT2887944T (lt) 2012-08-21 2013-08-21 Alopregnanolonas, skirtas atsparios epileptinės būklės gydymui
ES13830765T ES2902684T3 (es) 2012-08-21 2013-08-21 Alopregnanolona para el tratamiento del estado epiléptico refractario
MX2015002252A MX2015002252A (es) 2012-08-21 2013-08-21 Metodos para tratar epilepsia o estado de epilepsia.
RU2015109956A RU2667010C2 (ru) 2012-08-21 2013-08-21 Способы лечения эпилепсии или эпилептического статуса
DK13830765.7T DK2887944T3 (da) 2012-08-21 2013-08-21 Allopregnanolon til behandling af refraktær status epilepticus
IL294306A IL294306B2 (en) 2012-08-21 2013-08-21 Methods of treating epilepsy or status epilepticus
IL275725A IL275725B (en) 2012-08-21 2013-08-21 Treatment methods for epilepsy and status epilepticus
KR1020207015890A KR102305359B1 (ko) 2012-08-21 2013-08-21 간질 또는 간질지속 상태를 치료하는 방법
HK15109426.8A HK1209025B (en) 2012-08-21 2013-08-21 Allopregnanolone for treating refractory status epilepticus
ZA2015/01188A ZA201501188B (en) 2012-08-21 2015-02-20 Methods of treating epilepsy or status epilepticus
IL237352A IL237352B (en) 2012-08-21 2015-02-22 Treatment methods for epilepsy and status epilepticus
PH12015500482A PH12015500482A1 (en) 2012-08-21 2015-03-05 Methods of treating epilepsy or status epilepticus
AU2018220028A AU2018220028B2 (en) 2012-08-21 2018-08-22 Methods of Treating Epilepsy or Status Epilepticus
IL264414A IL264414B (en) 2012-08-21 2019-01-22 Treatment methods for epilepsy and status epilepticus
PH12020500065A PH12020500065A1 (en) 2012-08-21 2020-01-07 Methods of treating epilepsy or status epilepticus
AU2020204359A AU2020204359A1 (en) 2012-08-21 2020-06-30 Methods of treating epilepsy or status epilepticus
CY20221100012T CY1125070T1 (el) 2012-08-21 2022-01-05 Αλλοπρεγνανολονη για την θεραπευτικη αντιμετωπιση της ανθεκτικης επιληπτικης καταστασης
AU2022202277A AU2022202277A1 (en) 2012-08-21 2022-04-05 Methods of treating epilepsy or status epilepticus

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261691545P 2012-08-21 2012-08-21
US61/691,545 2012-08-21
US201361789491P 2013-03-15 2013-03-15
US61/789,491 2013-03-15

Publications (2)

Publication Number Publication Date
WO2014031792A2 true WO2014031792A2 (en) 2014-02-27
WO2014031792A3 WO2014031792A3 (en) 2014-04-10

Family

ID=50148516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/056062 Ceased WO2014031792A2 (en) 2012-08-21 2013-08-21 Methods of treating epilepsy or tatus epilepticus

Country Status (27)

Country Link
US (5) US20140057885A1 (enExample)
EP (2) EP3957309A1 (enExample)
JP (3) JP6355633B2 (enExample)
KR (2) KR102121633B1 (enExample)
CN (2) CN111529537A (enExample)
AU (4) AU2013305767B2 (enExample)
BR (2) BR112015003747A2 (enExample)
CA (1) CA2882708A1 (enExample)
CY (1) CY1125070T1 (enExample)
DK (1) DK2887944T3 (enExample)
ES (1) ES2902684T3 (enExample)
HR (1) HRP20220005T1 (enExample)
HU (1) HUE056838T2 (enExample)
IL (5) IL275725B (enExample)
LT (1) LT2887944T (enExample)
MX (1) MX2015002252A (enExample)
NZ (1) NZ705410A (enExample)
PH (2) PH12015500482A1 (enExample)
PL (1) PL2887944T3 (enExample)
PT (1) PT2887944T (enExample)
RS (1) RS62761B1 (enExample)
RU (1) RU2667010C2 (enExample)
SG (2) SG11201501911RA (enExample)
SI (1) SI2887944T1 (enExample)
SM (1) SMT202200006T1 (enExample)
WO (1) WO2014031792A2 (enExample)
ZA (1) ZA201501188B (enExample)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2806877A4 (en) * 2012-01-23 2016-02-17 Sage Therapeutics Inc NEUROACTIVE STEROID FORMULATIONS AND METHOD FOR TREATING DISORDERS OF THE CNS
WO2016205721A1 (en) 2015-06-18 2016-12-22 Sage Therapeutics, Inc. Neuroactive steroid solutions and their methods of use
JP2017526703A (ja) * 2014-09-08 2017-09-14 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物およびその使用
WO2018013615A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
JP2018505901A (ja) * 2015-02-17 2018-03-01 バンダ・ファーマシューティカルズ・インコーポレイテッドＶａｎｄａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 統合失調症の治療のためのイロペリドン
WO2019051477A1 (en) * 2017-09-11 2019-03-14 Sage Therapeutics, Inc. METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION
US10251894B2 (en) 2012-11-30 2019-04-09 The Regents Of The University Of California Anticonvulsant activity of steroids
WO2019075362A1 (en) 2017-10-12 2019-04-18 Sage Therapeutics, Inc. METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US10940156B2 (en) 2016-03-08 2021-03-09 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3885352A1 (en) 2014-10-16 2021-09-29 Sage Therapeutics, Inc. A compound, compositions thereof and this compound for use in methods of treating cns disorders
WO2021195301A1 (en) 2020-03-25 2021-09-30 Sage Therapeutics, Inc. Use of gabaa modulators for treatment of respiratory conditions
CN113925832A (zh) * 2020-07-13 2022-01-14 苏州特瑞药业有限公司 一种别孕烯醇酮的脂质体及其制备方法
WO2023060020A1 (en) * 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of established status epilepticus
US11945836B2 (en) 2014-11-27 2024-04-02 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US12048706B2 (en) 2012-08-21 2024-07-30 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
US12060386B2 (en) 2017-12-08 2024-08-13 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US12201640B2 (en) 2013-04-17 2025-01-21 Sage Therapeutics, Inc. 19-nor C3,3-disubstituted C21-n-pyrazolyl steroids and methods of use thereof
US12358942B2 (en) 2016-08-23 2025-07-15 Sage Therapeutics, Inc. Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid
US12473327B2 (en) 2014-06-18 2025-11-18 Sage Therapeutics, LLP Neuroactive steroids, compositions and uses thereof

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959966B1 (en) 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolone formulations and methods for the making and use thereof
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
US10172870B2 (en) 2014-09-02 2019-01-08 The Texas A&M University System Method of treating organophosphate intoxication by administration of neurosteroids
DK3229790T3 (da) 2014-12-08 2019-12-16 Nestle Sa Sammensætninger omfattende mediumkæde triglycerider til anvendelse i behandlingen af epilepsi
US10668041B2 (en) 2014-12-08 2020-06-02 Societe Des Produits Nestle Sa Compositions and methods comprising medium chain triglycerides for treatment of epilepsy
CN115487313A (zh) * 2015-02-06 2022-12-20 马瑞纳斯制药公司 静脉内加奈索酮制剂及其用途
CA3001722A1 (en) 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
US20180042903A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2019094724A1 (en) * 2017-11-10 2019-05-16 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disoders
WO2020113099A1 (en) * 2018-11-29 2020-06-04 Gary Aaron Howard Method for treating or preventing seizures associated with an epileptic disorder
US11446262B2 (en) 2018-11-29 2022-09-20 Debora Zucco Sassi Yonezawa Siviglia Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
IL293525A (en) 2019-12-06 2022-08-01 Marinus Pharmaceuticals Inc Ganaxolone for use in the treatment of multiple sclerosis complex
CN113368084A (zh) * 2020-03-10 2021-09-10 上海喀露蓝科技有限公司 含有大麻二酚，丙泊酚前药和别孕烯醇酮前药化合物的药物组合物及其在医药上的应用
CN115884766A (zh) * 2020-05-29 2023-03-31 睿升公司 用于使用中链甘油三酯治疗婴儿痉挛的方法
WO2022109440A1 (en) * 2020-11-23 2022-05-27 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of super refractory status epilepticus
TWI804037B (zh) * 2021-11-02 2023-06-01 長庚醫療財團法人高雄長庚紀念醫院 生酮飲食之評估系統及其運作方法

Family Cites Families (198)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3117142A (en) 1961-03-01 1964-01-07 Roussel Uclaf Novel preparation of estradiol and estrone
US3169134A (en) 1963-03-21 1965-02-09 Searle & Co 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
BE754111A (fr) 1969-07-29 1971-01-29 Upjohn Co Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
US3943124A (en) 1970-12-17 1976-03-09 Gordon Hanley Phillipps Chemical compounds
US3983111A (en) 1972-05-05 1976-09-28 Glaxo Laboratories Limited Steroidal anaesthetics of the pregnane and 19-norpregnane series
GB1430942A (en) 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
US3865939A (en) 1973-02-23 1975-02-11 Procter & Gamble Edible oils having hypocholesterolemic properties
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
US4192871A (en) 1976-01-06 1980-03-11 Glaxo Laboratories Limited Chemical compounds
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
US5847009A (en) 1986-01-14 1998-12-08 Alliance Pharmaceutical Corp. Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions
SE8600632D0 (sv) 1986-02-13 1986-02-13 Kabivitrum Ab Novel pharmaceutical composition
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
EP0603312A4 (en) 1991-09-13 1995-06-07 Cocensys Inc NEW GABA A RECEPTOR WITH STEROID BINDING POINTS.
JP4008024B2 (ja) 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Ｇａｂａａレセプター複合体と相互作用させるための化合物
EP0656365B1 (en) 1993-12-02 1997-04-09 Akzo Nobel N.V. Substituted 2beta-morpholinoandrostane derivatives
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
DK1038880T3 (da) 1994-02-14 2008-03-03 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
JP3696884B2 (ja) 1994-03-25 2005-09-21 アイソテクニカ、インコーポレーテッド ジュウテリウム化による薬物の効能の増強
WO1996003421A1 (en) 1994-07-21 1996-02-08 Pharmacia & Upjohn Company Neurologically active aminosteroids
GEP20002033B (en) 1994-11-23 2000-04-10 Cocensys Inc Us Androstane and Pregnane Series Compounds for Allosteric Modulation of GABA Receptor
US6780853B1 (en) * 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
CA2223996A1 (en) 1995-06-06 1996-12-19 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series
EP0840612A1 (en) 1995-07-24 1998-05-13 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
WO1998005337A1 (en) 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US7630757B2 (en) * 1997-01-06 2009-12-08 Flint Hills Scientific Llc System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6316613B1 (en) 1997-07-25 2001-11-13 Beckman Coulter, Inc. Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis
US6245757B1 (en) 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
WO1999045931A1 (en) 1998-03-11 1999-09-16 Baeckstroem Torbjoern Epiallopregnanolone in the treatment of cns disorders
US20020198174A1 (en) 2001-05-07 2002-12-26 Allergan Sales, Inc. Disinfecting and solubilizing steroid compositions
US6376531B1 (en) 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
EP1104760B1 (en) 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
US6442887B2 (en) 2000-02-25 2002-09-03 Robert L. Sanquist Live bait keeper
IN187686B (enExample) 2000-06-21 2002-06-08 Bharat Serums & Vaccines Ltd
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US20020072509A1 (en) 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
GR1003861B (el) * 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
CA2443266A1 (en) 2001-02-13 2002-08-22 University Of Florida A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
EP1392260A2 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of benzodiazepines through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
CA2641760A1 (en) 2001-05-24 2002-11-28 Alexza Pharmaceuticals, Inc. Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
JP2003063965A (ja) 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
CA2472184C (en) 2002-01-14 2011-04-19 David Mark Lucas Magnetically detectable latex articles
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
US20040138187A1 (en) 2002-08-28 2004-07-15 Reading Christopher L. Therapeutic treatment methods
US9339508B2 (en) 2003-01-17 2016-05-17 Mapreg Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury
US7781421B2 (en) 2003-05-29 2010-08-24 Washington University Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods
WO2005011612A2 (en) * 2003-07-31 2005-02-10 The Research Foundation Of State University Of New York Alpha 4 beta 2 delta gaba-a receptors as a strategy for pms and alcoholism
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US7892483B2 (en) 2004-03-12 2011-02-22 Cipla Limited Sterilization process
US20090118248A1 (en) 2004-04-23 2009-05-07 Euro-Celtique S.A. 3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
ITMI20041763A1 (it) 2004-09-16 2004-12-16 Altergon Sa Nuove formulazioni iniettabili contenenti progesterone
US20060063707A1 (en) 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
WO2006037016A2 (en) 2004-09-27 2006-04-06 The Regents Of The University Of California Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
US8557861B2 (en) 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
EP2471536A1 (en) 2004-09-29 2012-07-04 Harbor BioSciences, Inc. Steroid analogs and characterization and treatment methods
WO2006088894A2 (en) 2005-02-15 2006-08-24 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
RS52471B (sr) 2005-03-24 2013-02-28 Emory University Režimi doziranja za lečenje traumatske povrede mozga progesteronom
AU2006235318A1 (en) * 2005-04-07 2006-10-19 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
US20110319386A1 (en) 2005-08-26 2011-12-29 Braincells Inc. Neurogenesis by muscarinic receptor modulation
EP1959966B1 (en) 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolone formulations and methods for the making and use thereof
KR20080077620A (ko) * 2005-12-05 2008-08-25 뉴로서치 에이/에스 벤즈이미다졸 및 ｇａｂａａ 수용체 복합체를 조절하기위한 이의 용도
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
US20070287931A1 (en) 2006-02-14 2007-12-13 Dilorenzo Daniel J Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
US20090074677A1 (en) 2007-01-08 2009-03-19 Duke University Neuroactive steroid compositions and methods of use therefor
US20090203658A1 (en) 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
US7813811B2 (en) 2007-02-08 2010-10-12 Neuropace, Inc. Refillable reservoir lead systems
DK3461503T3 (da) 2007-04-11 2022-02-14 Biomarin Pharm Inc Fremgangsmåder til indgivelse af tetrahydrobiopterin, associerede sammensætninger og målingsfremgangsmåder
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
EP2167098B1 (en) 2007-06-11 2018-09-05 University Of Southern California Allopregnanolone in a method for enhancing neurological function (alzheimer disease)
CA2698172C (en) 2007-06-15 2014-02-18 Cook, Kevin M. Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
US20100316678A1 (en) 2007-06-28 2010-12-16 Cnsbio Pty Ltd. Combination methods and compositions for treatment of neuropathic pain
CN101795565A (zh) * 2007-06-28 2010-08-04 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
EP2254577A1 (en) 2007-12-26 2010-12-01 Eisai R&D Management Co., Ltd. Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
RU2470642C2 (ru) 2008-01-03 2012-12-27 Байомарин Фармасьютикл Инк. Аналоги птерина для лечения состояния, чувствительного к вн4
US20090198145A1 (en) 2008-02-06 2009-08-06 Chow Harrison Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
US8729070B2 (en) 2008-02-20 2014-05-20 Targia Pharmaceuticals CNS pharmaceutical compositions and methods of use
DE102008015366A1 (de) 2008-03-20 2009-09-24 Merck Patent Gmbh Lyophilisierte Nanoemulsion
CZ301216B6 (cs) 2008-07-10 2009-12-09 Ústav organické chemie a biochemie Akademie ved CR, v. v. i. Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
WO2010014913A1 (en) * 2008-08-01 2010-02-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
PL2356109T3 (pl) * 2008-10-10 2017-07-31 Vm Discovery, Inc. Kompozycje i sposoby leczenia zaburzeń używania alkoholu, bólu i innych chorób
CN102300566A (zh) * 2008-11-30 2011-12-28 O·扎查尔 血管收缩剂的皮肤应用
US20110306579A1 (en) * 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
US20120142645A1 (en) 2009-03-17 2012-06-07 Marx Christine E Neuroactive steroid compositions and methods of use for lowering cholesterol
US20110152840A1 (en) 2009-12-23 2011-06-23 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
RU2574022C2 (ru) * 2010-01-21 2016-01-27 Дробридж Фармасьютикалз Пти Лтд. Анестезирующий состав
JP5832547B2 (ja) * 2010-11-03 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 薬剤を含有する針カニューレ
US20130309306A1 (en) 2010-12-01 2013-11-21 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
CZ303443B6 (cs) 2011-02-15 2012-09-12 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
US9388210B2 (en) 2011-02-25 2016-07-12 Washington University Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
FR2973031B1 (fr) 2011-03-23 2013-11-29 Univ Strasbourg Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
US9084797B2 (en) 2011-05-23 2015-07-21 Besins Healthcare Luxembourg Sarl Progesterone treatment for improving sleep quality
KR20130002292A (ko) 2011-06-28 2013-01-07 주식회사 비보존 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
CA2843436A1 (en) 2011-07-29 2013-02-07 The Regents Of The University Of California Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors
WO2013036835A1 (en) 2011-09-08 2013-03-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
CN113234114A (zh) 2011-10-14 2021-08-10 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
CA2856592C (en) 2011-11-29 2017-05-30 Amino Up Chemical Co., Ltd. Vicenin 2 and analogues thereof for use as an antispasmodic and/or prokinetic agent
CA2862076C (en) 2012-01-23 2020-04-21 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating cns disorders
WO2013188792A2 (en) 2012-06-15 2013-12-19 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
PL2887944T3 (pl) 2012-08-21 2022-02-21 Sage Therapeutics, Inc. Allopregnanolon do leczenia lekoopornego stanu padaczkowego
US9765110B2 (en) 2012-10-08 2017-09-19 Washington University Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
US9757391B2 (en) 2012-11-09 2017-09-12 Goodchild Investments Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
JP2016501876A (ja) 2012-11-30 2016-01-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ステロイドの抗痙攣活性
SG10201706063UA (en) 2012-12-18 2017-09-28 Univ Washington Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
WO2014108808A2 (en) 2013-01-09 2014-07-17 Henry James Lorne Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
WO2014169832A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
MX362543B (es) 2013-04-17 2019-01-24 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos.
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
HRP20210610T1 (hr) 2013-07-19 2021-05-28 Sage Therapeutics, Inc. Neuroaktivni steroidi, pripravci i njihove uporabe
PT3035940T (pt) 2013-08-23 2019-01-28 Sage Therapeutics Inc Esteroides neuroativos, composições e seus usos
SG10201803812TA (en) 2014-05-29 2018-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP3885352B1 (en) 2014-10-16 2024-11-27 Sage Therapeutics, Inc. A compound, compositions thereof and this compound for use in methods of treating cns disorders
EP4275748A3 (en) 2014-10-16 2024-01-03 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
RS60343B1 (sr) 2014-11-27 2020-07-31 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
SMT202100113T1 (it) 2015-01-26 2021-05-07 Sage Therapeutics Inc Composizioni e metodi per trattare disturbi del snc
CN115487313A (zh) 2015-02-06 2022-12-20 马瑞纳斯制药公司 静脉内加奈索酮制剂及其用途
EP3258939B1 (en) 2015-02-20 2022-09-07 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3280420B1 (en) 2015-04-10 2024-03-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MA45276A (fr) 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
GB2541015A (en) 2015-08-06 2017-02-08 Ge Oil & Gas Uk Ltd Subsea flying lead
JP6957455B2 (ja) 2015-10-14 2021-11-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ ベータ細胞の複製及び／または生存の亢進
MA43284A (fr) 2015-11-20 2018-09-26 Sage Therapeutics Inc Composés et leurs méthodes d'utilisation
CN113616661A (zh) 2016-03-08 2021-11-09 萨奇治疗股份有限公司 神经活性类固醇、其组合物及用途
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
AU2017296295B2 (en) 2016-07-11 2022-02-24 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
US20180042903A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US20180050107A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Neurosteroid compositions and methods of use thereof
US20180050005A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
JOP20190022B1 (ar) 2016-08-23 2023-03-28 Sage Therapeutics Inc ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري
NZ751690A (en) 2016-09-07 2022-02-25 Glia Llc Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2018169798A1 (en) 2017-03-11 2018-09-20 The Regents Of The University Of California Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers
KR20190137839A (ko) 2017-04-18 2019-12-11 마리누스 파마슈티컬스 인코포레이티드 지속 방출 주사용 뉴로스테로이드 제제
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US11752115B2 (en) 2017-06-21 2023-09-12 The Board Of Trustees Of The University Of Illinois PPAR-alpha agonist treatment of neuropsychiatric disorders
WO2018237282A1 (en) 2017-06-23 2018-12-27 The Board Of Trustees Of The University Of Illinois Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
US11992495B2 (en) 2017-06-23 2024-05-28 The Regents Of The University Of California Enhancing GABA's ability to modulate immune responses
EP3678670A1 (en) 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
US20200276209A1 (en) 2017-09-11 2020-09-03 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
AU2018334214A1 (en) 2017-09-14 2020-03-26 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
WO2019094724A1 (en) 2017-11-10 2019-05-16 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disoders
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
AU2018392093B2 (en) 2017-12-22 2024-02-01 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
CN118271387A (zh) 2017-12-22 2024-07-02 萨奇治疗股份有限公司 治疗cns疾病的组合物和方法
US11718642B2 (en) 2018-01-12 2023-08-08 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
TW202014192A (zh) 2018-05-04 2020-04-16 加拿大商阿爾宙斯製藥有限公司 神經類固醇衍生物及其用途
CN117959309A (zh) 2018-06-12 2024-05-03 萨奇治疗股份有限公司 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
EP4321519A3 (en) 2018-10-12 2024-05-01 Sage Therapeutics, Inc. Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
MX2021004452A (es) 2018-10-19 2021-08-11 Sage Therapeutics Inc Esteroides neuroactivos no saturados 9(11) y sus métodos de uso.
JP2022506944A (ja) 2018-11-08 2022-01-17 ヴァーソナ セラピューティクス，インコーポレーテッド ５－α－レダクターゼ阻害剤の局所製剤及びそれらの使用
MX2021005992A (es) 2018-11-21 2021-09-14 Certego Therapeutics Inc Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
TW202521129A (zh) 2018-12-05 2025-06-01 美商賽吉醫療公司 神經活性類固醇及其使用方法
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
SG11202106306YA (en) 2018-12-14 2021-07-29 Acerus Biopharma Inc Active ester derivatives of testosterone, compositions and uses thereof
US20220372067A1 (en) 2018-12-21 2022-11-24 Sage Therapeutics, Inc. 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof
TW202523658A (zh) 2019-05-24 2025-06-16 美商賽吉醫療公司 化合物、組合物及使用方法
AR119047A1 (es) 2019-05-31 2021-11-17 Sage Therapeutics Inc Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc
CN114787174A (zh) 2019-06-27 2022-07-22 萨奇治疗股份有限公司 用于治疗cns病症的组合物和方法
CA3143545A1 (en) 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compounds for treating cns disorders
US20230303616A9 (en) 2019-06-27 2023-09-28 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CN114761019A (zh) 2019-12-05 2022-07-15 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
JP2023518411A (ja) 2020-03-18 2023-05-01 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド及びその使用方法
EP4125921A1 (en) 2020-03-25 2023-02-08 Sage Therapeutics, Inc. Use of agents for treatment of respiratory conditions
WO2021262836A1 (en) 2020-06-24 2021-12-30 Sage Therapeutics, Inc. 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof
AR123018A1 (es) 2020-07-20 2022-10-26 Sage Therapeutics Inc Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este
AU2021385335A1 (en) 2020-11-25 2023-06-29 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2022165017A1 (en) 2021-01-28 2022-08-04 Sage Therapeutics, Inc. Use of neuroactive steroids for treatment of sexual dysfunction
US20240148756A1 (en) 2021-02-18 2024-05-09 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction
BR112023018607A2 (pt) 2021-03-17 2023-10-24 Sage Therapeutics Inc Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior
AU2022258203A1 (en) 2021-04-12 2023-10-26 Sage Therapeutics, Inc. Treatment of essential tremor
CA3217866A1 (en) 2021-04-29 2022-11-03 Sage Therapeutics, Inc. Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female
IL307991A (en) 2021-04-29 2023-12-01 Sage Therapeutics Inc 19-NOR C3, 3- di-converted C21-N-pyrazolyl steroid for use in the treatment of major depressive disorder and postpartum depression
WO2023158668A1 (en) 2022-02-16 2023-08-24 Sage Therapeutics, Inc. Neuroactive steroids for treatment of cns-related disorders
WO2023163879A1 (en) 2022-02-28 2023-08-31 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2887944A4 *

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
US10322139B2 (en) 2012-01-23 2019-06-18 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating CNS disorders
EP4295908A3 (en) * 2012-01-23 2024-03-20 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
US11426417B2 (en) 2012-01-23 2022-08-30 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating CNS disorders
EP2806877A4 (en) * 2012-01-23 2016-02-17 Sage Therapeutics Inc NEUROACTIVE STEROID FORMULATIONS AND METHOD FOR TREATING DISORDERS OF THE CNS
EP3650027A1 (en) * 2012-01-23 2020-05-13 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
US12048706B2 (en) 2012-08-21 2024-07-30 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
US10251894B2 (en) 2012-11-30 2019-04-09 The Regents Of The University Of California Anticonvulsant activity of steroids
US12201640B2 (en) 2013-04-17 2025-01-21 Sage Therapeutics, Inc. 19-nor C3,3-disubstituted C21-n-pyrazolyl steroids and methods of use thereof
US12473327B2 (en) 2014-06-18 2025-11-18 Sage Therapeutics, LLP Neuroactive steroids, compositions and uses thereof
JP2017526703A (ja) * 2014-09-08 2017-09-14 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物およびその使用
US12083131B2 (en) 2014-09-08 2024-09-10 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JP2020059760A (ja) * 2014-09-08 2020-04-16 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物およびその使用
JP2022113879A (ja) * 2014-09-08 2022-08-04 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物およびその使用
EP3885352A1 (en) 2014-10-16 2021-09-29 Sage Therapeutics, Inc. A compound, compositions thereof and this compound for use in methods of treating cns disorders
EP4527461A2 (en) 2014-10-16 2025-03-26 Sage Therapeutics, Inc. A compound, compositions thereof and this compound for use in methods of treating cns disorders
US11945836B2 (en) 2014-11-27 2024-04-02 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10987346B2 (en) 2015-02-17 2021-04-27 Vanda Pharmaceuticals Inc. Iloperidone for the treatment of schizophrenia
JP2018505901A (ja) * 2015-02-17 2018-03-01 バンダ・ファーマシューティカルズ・インコーポレイテッドＶａｎｄａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 統合失調症の治療のためのイロペリドン
WO2016205721A1 (en) 2015-06-18 2016-12-22 Sage Therapeutics, Inc. Neuroactive steroid solutions and their methods of use
US11554125B2 (en) 2016-03-08 2023-01-17 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JP2023093723A (ja) * 2016-03-08 2023-07-04 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
US10940156B2 (en) 2016-03-08 2021-03-09 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP4406602A2 (en) 2016-07-11 2024-07-31 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
EP4302764A2 (en) 2016-07-11 2024-01-10 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
WO2018013615A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
US12358942B2 (en) 2016-08-23 2025-07-15 Sage Therapeutics, Inc. Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid
US20200276209A1 (en) * 2017-09-11 2020-09-03 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
WO2019051477A1 (en) * 2017-09-11 2019-03-14 Sage Therapeutics, Inc. METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION
WO2019075362A1 (en) 2017-10-12 2019-04-18 Sage Therapeutics, Inc. METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS
US12060386B2 (en) 2017-12-08 2024-08-13 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11571432B2 (en) 2019-09-30 2023-02-07 Eliem Therapeutics (UK) Ltd Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US11090314B2 (en) 2019-09-30 2021-08-17 Eliem Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
WO2021195301A1 (en) 2020-03-25 2021-09-30 Sage Therapeutics, Inc. Use of gabaa modulators for treatment of respiratory conditions
CN113925832B (zh) * 2020-07-13 2023-06-16 苏州特瑞药业股份有限公司 一种别孕烯醇酮的脂质体及其制备方法
CN113925832A (zh) * 2020-07-13 2022-01-14 苏州特瑞药业有限公司 一种别孕烯醇酮的脂质体及其制备方法
WO2023060020A1 (en) * 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of established status epilepticus

Also Published As

Publication number Publication date
ZA201501188B (en) 2016-09-28
AU2020204359A1 (en) 2020-07-23
IL237352A0 (en) 2015-04-30
AU2018220028B2 (en) 2020-04-02
HK1209025A1 (en) 2016-03-24
CY1125070T1 (el) 2023-06-09
RU2018132041A3 (enExample) 2022-03-31
PL2887944T3 (pl) 2022-02-21
EP2887944A4 (en) 2016-02-10
HUE056838T2 (hu) 2022-04-28
PT2887944T (pt) 2022-01-10
US20250161325A1 (en) 2025-05-22
BR112015003747A2 (pt) 2017-07-04
US20190269699A1 (en) 2019-09-05
IL275725B (en) 2022-08-01
EP2887944A2 (en) 2015-07-01
JP2021059608A (ja) 2021-04-15
MX2015002252A (es) 2015-07-21
US20190038639A1 (en) 2019-02-07
CN111529537A (zh) 2020-08-14
JP2015527371A (ja) 2015-09-17
DK2887944T3 (da) 2022-01-03
SI2887944T1 (sl) 2022-02-28
IL294306B2 (en) 2024-01-01
IL264414B (en) 2020-07-30
AU2018220028A1 (en) 2018-09-06
IL264414A (en) 2019-02-28
SMT202200006T1 (it) 2022-03-21
KR102121633B1 (ko) 2020-06-10
PH12020500065A1 (en) 2021-04-26
JP6355633B2 (ja) 2018-07-11
SG10201608148TA (en) 2016-11-29
AU2013305767A1 (en) 2015-03-19
IL294306A (en) 2022-08-01
BR122021022560B1 (pt) 2022-08-09
JP2018154652A (ja) 2018-10-04
EP3957309A1 (en) 2022-02-23
ES2902684T3 (es) 2022-03-29
IL275725A (en) 2020-08-31
LT2887944T (lt) 2022-01-10
SG11201501911RA (en) 2015-04-29
IL294306B1 (en) 2023-09-01
US20140057885A1 (en) 2014-02-27
PH12015500482A1 (en) 2015-04-20
RU2667010C2 (ru) 2018-09-13
AU2022202277A1 (en) 2022-04-21
CN104736159A (zh) 2015-06-24
RU2015109956A (ru) 2016-10-20
HRP20220005T1 (hr) 2022-04-01
RS62761B1 (sr) 2022-01-31
RU2018132041A (ru) 2018-11-13
US20220152050A1 (en) 2022-05-19
AU2013305767B2 (en) 2018-05-24
WO2014031792A3 (en) 2014-04-10
KR20150054846A (ko) 2015-05-20
CA2882708A1 (en) 2014-02-27
JP6829224B2 (ja) 2021-02-10
KR102305359B1 (ko) 2021-09-24
IL304912A (en) 2023-10-01
EP2887944B1 (en) 2021-10-06
NZ705410A (en) 2018-03-23
KR20200067922A (ko) 2020-06-12
US12048706B2 (en) 2024-07-30
IL237352B (en) 2019-05-30

Similar Documents

Publication Publication Date Title
US12048706B2 (en) Methods of treating epilepsy or status epilepticus
JP7343651B2 (ja) 向神経活性ステロイド製剤およびｃｎｓ障害の処置方法
WO2019051477A1 (en) METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION
HK40070783A (en) Preparation of a composition comprising allopregnanolone and sulfobutylether-beta-cyclodextrin
RU2824132C2 (ru) Способы лечения эпилепсии или эпилептического статуса
HK1209025B (en) Allopregnanolone for treating refractory status epilepticus
HK40104404A (en) Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
HK40029922A (en) Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
HK1204281B (en) Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13830765

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2882708

Country of ref document: CA

Ref document number: 2015528638

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/002252

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 237352

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2013830765

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12015500482

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2013305767

Country of ref document: AU

Date of ref document: 20130821

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20157007115

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2015109956

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015003747

Country of ref document: BR

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13830765

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112015003747

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150223

WWW Wipo information: withdrawn in national office

Ref document number: 304912

Country of ref document: IL